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ABSTRACT 
Background and purpose: As the skin cancer burden continues to increase, there is an urgent need for 
novel methods for the early detection of skin cancers, and for new cost-effective treatments. The 
hyperspectral imaging system (HIS) is a novel technique, which offers the dual advantages of allowing the 
imaging of large skin areas rapidly and non-invasively. Daylight photodynamic therapy (DL-PDT), with the 
advantages of excellent tolerability and convenience, is an attaractive therapy for actinic keratoses (AK) and 
field cancerization.This thesis aimed to enable early and effective treatment of common premalignancies of 
photo-damaged skin.The first purpose of this thesis was to evaluate the feasibility of HIS in the detection of 
field cancerized skin and in the detection of ill-defined borders of lentigo maligna (LM) and lentigo maligna 
melanoma (LMM). In addition, this thesis aimed to further develop the treatment of field cancerized skin 
with photodynamic therapy using a novel photosensitizer in combination with daylight (DL-PDT), and to 
evaluate the cost-effectiveness of DL-PDT.  
Methods: This thesis included four non-sponsored prospective clinical studies. The novel prototype HIS, 
used in studies I-II, was developed for the study at the VTT Technical Research Centre of Finland. The 
technique enabled in vivo imaging of the skin prior to surgical procedures and produced abundance maps of 
the affected skin areas. The results were verified by histopathology. Study III was a randomized double-
blinded intra-individual split-face trial comparing novel photosensitizer formulation, 5-aminolaevulinate 
nanoemulsion (BF-200 ALA) with methyl-5-aminolaevulinate (MAL) in DL-PDT of AKs. In addition to 
blinded clinical and histological treatment efficacy, tolerability of the treatment was assessed. Study IV 
evaluated the cost-effectiveness of MAL-DL-PDT compared to conventional MAL-LED-PDT. 
Results: In studies I-II HIS showed its feasibility in both the detection of subclinical borders of ill-defined 
lentigo malignas (LM) and lentigo maligna melanomas (LMM), and in the detection of early subclinical 
actinic keratoses (AK). In study I HIS accurately detected 20 of 23 (87%) of the LM/LMM borders as 
confirmed by histology.  HIS was useful i.e. detected the lesion borders more accurately than a clinician 
using Wood’s light in 11 of 23 (47.8%) cases. Six re-excisions could have been avoided with HIS. In 3/23 
cases (13%) HIS was not in concordance with the histopathology, while in two cases HIS showed lesion 
extensions which were not verified histologically (wrong positive) and in one case HIS missed the 
subclinical extension (wrong negative).  In study II with 12 patients and 52 clinical AKs, HIS accurately 
detected all the clinical lesions in addition to numerous areas of subclinical damage. HIS findings matched 
the histopathological findings in all 33 biopsied areas (AK, n=28, photo-damaged skin, n=5), revealing 16 
subclinical lesions of which 10 were not detected by fluorescence diagnosis.  
In study III (13 patients, 177 lesions) in a per patient (half-face) analysis BF-200 ALA cleared thin AKs 
more effectively than did MAL (p=0.027). In per lesion analysis the complete clearance rates were 84.5% for 
BF-200 ALA, and 74.2% for MAL (p=ns). The area response rates, including also the new appeared lesions 
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(i.e.preventive effect), were 79.8% for BF-200 ALA and 65.6% for MAL, p=0.044. Histologically, DL-PDT 
effectively cleared all the signs of dysplasia in 61.5% lesions treated with BF-200 ALA and in 38.5% with 
MAL (p=ns). The mean decrease in p53 expression was 54.4% with BF-200 ALA, 34 % with MAL (p=ns). 
DL-treatment was nearly painless with both photosensitizers. BF-200 ALA and MAL DL-treatments were 
similarly tolerated as regards to adverse reactions. 
In study IV 70 patients (210 target lesions) randomized to receive DL-PDT or LED-PDT with MAL, at six 
months the patient complete response rates were 15 of 35 (42.9%) and 24 of 35 (68.6%), (p=0.030) and 
lesion clearance rates were 72.4% and  89.2%,  respectively (p=0.0025). DL-PDT required significantly less 
time at the clinic (p<0.0001) and could be used with lower total costs (€132) compared to conventional LED-
PDT (€170), p=0.022. However, in terms of cost-effectiveness MAL-DL-PDT was found to give less value 
for money compared to MAL-LED-PDT.  The incrementl cost-effectiveness ratio (ICER) showed a 
monetary gain of €147 per unit of effectiveness lost. Thus, the use of DL-PDT instead of LED-PDT would 
decrease the healing probability but only low incremental cost savings would be achieved. The costs per 
complete responder were €308 for MAL DL-PDT and €248 for MAL LED-PDT, p= 0.004.  
Conclusions: The more accurate pre-surgical assessment of the subclinical borders of LM and LMM with 
HIS could lead to fewer re-excixions, which furthermore could reduce the burden to both patients and 
clinics. In addition, the early non-invasive detection of skin field cancerization could enhance the treatment 
process by revealing the as yet subclinical areas in need of treatment, and could possibly aid the monitoring 
of treatment efficacy. Even though HIS was found to be useful in these two indications, more studies are 
warranted to qualify the optimal mathematical algorithms for diagnostic use. The use of a novel 
photosensitizer formulation, BF-200 ALA, in DL-PDT could lead to lower costs and increase the efficacy. 
Interestingly, the efficacy of DL-PDT with BF-200 ALA was approaching the efficacy achieved with 
conventional LED-PDT. As field cancerized skin should be treated as a chronic disease requiring repeated 
treatments, DL-PDT offers a painless and convenient option for this purpose.  However, DL-PDT with MAL 
provided less value for money compared to conventional MAL-PDT. The cost-effectiveness of BF-200 ALA 
in DL-PDT for AKs needs further studies. 
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TIIVISTELMÄ 
Ihosyöpien määrä on jatkuvassa räjähdysmäisessä kasvussa maailmanlaajuisesti.  Tämä kuormittaa 
terveydenhuoltoa merkittävästi. Taudinmäärityksen kehittäminen, siten että ihosyövät pystytään 
tunnistamaan jo varhaisessa vaiheessa sekä hoitoalueiden aiempaa tarkempi määrittäminen lisähoitojen 
välttämiseksi, ovat keskeisiä keinoja rajoittaa hoitokustannuksia. Lisäksi on tarve uusille, helposti 
toteutettaville ja kustannusvaikuttaville hoitomuodoille.  
Väitöstyössä tutkittiin uutta Suomessa kehitettyä hyperspektritekniikkaa ihon okasolusyövän varhaisasteiden, 
ns. subkliinisten aktiinikeratoosien, tunnistamisessa, sekä huonosti rajautuvien ihon pintamelanoomien, ns. 
lentigo malignojen, rajojen määrittämisessä lisäleikkausten välttämiseksi. Väitöstyössä selvitettiin myös 
uuden päivänvalolla toteutettavan fotodynaamisen hoidon (päivänvalo-PDT) tehoa ja turvallisuutta, sekä 
kustannusvaikuttavuutta ihon okasolusyövän esiasteiden eli aktiinikeratoosien hoidossa. Tutkimuksessa 
tutkittiin kahta iholle levitettävää valoherkistäjävoidetta, joista toista ei aiemmin ole käytetty tällä 
indikaatiolla. Tutkimuksella haluttiin kehittää ihosyöpien varhaisvaiheiden hoitoprosessia resursseja ja 
kustannuksia säästäväksi, sekä löytää uusia, hyvin siedettyjä mutta tehokkaita hoitomuotoja. 
Väitöskirjatyöhön sisältyi neljä prospektiivista kliinistä tutkimusta.  
Hyperspektrikuvantaminen todettiin hyödylliseksi varhaisten, silmälle vielä näkymättömien, 
aktiinikeratoosien havaitsemisessa. Lisäksi hyperspektrikuvantamisen avulla kyettiin havaitsemaan silmälle 
näkymättömiä lentigo maligna-kasvainten rajoja. Tämä auttaa entistä tarkemmin määrittämään hoitoalueet ja 
saattaa mahdollistaa entistä tarkemman hoidon seurannan. Turhilta lisäleikkauksilta saatetaan välttyä. 
Päivänvalo-PDT osoittautui tehokkaaksi, turvalliseksi ja paremmin siedetyksi kuin perinteinen 
fotodynaaminen hoito (keinovalo-PDT), missä valolähteenä on keinovalo. Päivänvalo-PDT vei vähemmän 
sekä poliklinikan henkilökunnan että potilaan aikaa. Keinovalo-PDT osoittautui kuitenkin 
kustannustehokkaammaksi kuin päivänvalohoito, kun lääkkeenä oli perinteinen valoherkistäjä, 
metyyliaminolevulinaatti (MAL). Uusi valoherkistäjälääkkeet, aminolevulinaatti nanoemulsio (BF-200 
ALA), osoittautui tehokkaaksi ja turvallisia aktiinikeratoosien päivänvalo-PDT:ssa.  
Hyperspektrikuvantaminen on lupaava uusi tekniikka silmälle näkymättömien ihosyöpien varhaisvaiheiden 
havaitsemissa sekä hoitoa tarvitsevan ihosyöpäalueen määrittämisessä. Päivänvalo-PDT mahdollistaa 
laajojen valovaurioalueiden hoidon tehokkaasti ja kivuttomasti. Uusien tehokkaiden valoherkistäjien käyttö 
saattaa parantaa hoitotehoa, laskea hoitokustannuksia ja siten lisätä hoidon kustannustehokkuutta. 
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INTRODUCTION 
Skin cancers are the most common cancers in fair-skinned populations worldwide (Kozma et al 2014,). An 
increase in skin cancer incidence has been a significant problem around the world, especially in countries 
with high levels of ultra-violet radiation (UVR) exposure, but also in northern countries. Currently, in 
Sweden skin cancers are a cause of greater mortality than traffic accidents (Eriksson et al 2014). The high 
incidence rates also bring a significant economical burden, Figure 1 (Gordon et al 2014, Erikson et al 2014).  
Due to aging of populations and increases in cumulative and habitual UVR-exposure, skin cancer incidence 
will continue to increase sharply in upcoming years (Gordon et al 2014, Mayer et al 2014). Consequently, 
the health care costs of skin cancer treatments are expected to expand dramatically. In Sweden the direct 
health care costs for skin cancers have increased by 23% over a 6-year period (2005-2011) causing 
approx.102 million euros total annual costs (Eriksson et al 2014). As the cost of treatment for metastatic skin 
cancers are very high and economically poor value for money more focus should be put on prevention and 
the treatment of skin cancers at their very early stages (Gordon et al 2014).  
 
Figure 1. Annual direct health care costs of skin cancer burden (million euros 2013). SCC=squamous cell carcinoma, 
BCC= basal cell carcinoma. From Gordon et al 2014, with the permission of Wolters Kluwer Health. 
Actinic keratoses (AK), regarded as early stage precursors of cutaneous squamous cell carcinoma (cSCC), 
are the most common premalignancies among humans  and  the third most frequent reason for visiting a 
dermatologist (Salasche 2000, Quaedvlieg et al 2006). AK prevalence among the elderly varies from approx. 
11-34% in the Northern hemisphere up to 50% in Australia (Frost et al 2000, Memon et al 2000, Schaefer et 
al 2014).  The total annual direct costs for AKs vary from 18 million euros in Sweden in 2011 to up to1.2 
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billion USD in the US in 2004 (Neidecker et al 2009, Eriksson et al 2014). AKs typically occur as multiple 
lesions in sun-damaged skin areas, typically in facial or scalp areas (Callen et al 1997).  As 25-75% of AK 
patients require repeated treatments, AKs should be treated as a chronic disease (Ceilley et al 2013). Thus, an 
ideal AK treatment has high clinical response rates with low recurrence with minimal side effects, good 
cosmetic outcome and low costs. 
AKs are the earliest clinically detectable areas of skin undergoing carcinogenesis. Skin field cancerization 
refers to the presence of early invisible changes on photo-damaged skin surrounding the visible AKs 
(Braakhuis et al 2003). Despite the relatively low transformation risk for a single AK lesion to develop into 
cSCC, the presence of multiple lesions in a sun-damaged field over several years increases the risk for the 
development of invasive and potentially metastatic cSCCs (Dodson et a 1991). Current guidelines 
recommend the use of field-directed therapies also targeting subclinical, non-apparent AKs instead of 
ablative lesion-targeted therapies (Braathen et al 2012, Stockfleth 2012, Ceilley et al 2013, Micali et al 
2014). Photodynamic therapy (PDT) offers several advantages in the treatment of AKs. Large field areas can 
be treated with high clearance rates, short treatment and adverse reaction periods, and excellent cosmetic 
outcome (Braathen et al 2012). Novel photosensitizers and the development of better tolerated treatment 
processes like daylight-PDT (DL-PDT), make PDT an even more appealing treatment choice (Szeimies et al 
20102, Wiegell et al 2008). 
Lentigo maligna (LM) and lentigo maligna melanoma (LMM) are the most common melanoma subtypes in 
the facial area, and like AKs, are also related to chronic sun-exposure.  Their location in sun-damaged skin 
poses both diagnostic and therapeutic challenges.  The presence of benign pigmented lesions in sun-damaged 
skin in the vicinity of LM is difficult to diagnose both clinically and histologically. In addition, the 
amelanotic subclinical extension of the lesions often leads to higher recurrence rates than for other 
melanomas (McKenna et al 2006).  
Histopathology, based on the detection of characteristics of sliced tissue using light microscopy, is the gold 
standard for the diagnosis of skin cancer. However, being an invasive and slow procedure, it has its 
limitations. Recently, many non-invasive diagnostic methods have emerged for skin cancer detection (Calin 
et al 2013).  
This thesis represents hyperspectral imaging as a novel non-invasive tool for the detection of field cancerized 
skin and ill-defined borders of lentigo malignas. In addition, this thesis aims to further develop PDT using a 
novel photosensitizer formulation in combination with daylight for the treatment of field cancerized skin.  
These approaches aim to enable early and effective treatment of common (pre)malignancies of photo-
damaged skin. Furhermore, this thesis evaluates the cost-effectiveness of DL-PDT and LED-PDT. 
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REVIEW OF THE LITERATURE 
1. ACTINIC KERATOSES AND FIELD CANCERIZATION 
1.1 Definitions and clinical characteristics 
Aktinic keratosis (AK) was first described byDubreuilh in 1896 as “the seed of cancer”. The histological 
continuum from AK (at that time named keratosis senilis) to cutaneous squamous cell carcinoma (cSCC) was 
first introduced by Freudenthal in 1926. In 1938 Sutton claimed that AK is an early superficial cSCC 
(Heaphy et al 2000). In 1958 Pinkus renamed keratosis senilis, actinic keratosis, meaning a thickened/scaly 
growth caused by electromagnetic irradiation. Since field cancerization was first presented in the upper 
gastro-intestinal tract in 1953, similar findings of multifocal precancerous changes surrounding the primary 
tumor have been described in several organs including the skin, oropharynx, esophagus, stomach, lung, 
colon, anus, cervix and bladder (Vatve et al 2007).    
 To date AKs are regarded as the earliest clinically detectable areas of dysplastic keratinocytes in the 
continuum towards invasive and potentially metastatic cSCCs (Callen et al 1997, Ulrich C 2009), Figure 2. 
Histologically, AKs represent dysplastic intraepithelial keratinocytes lacking dermal invasion (Cockerell 
2000). Clinically AKs appear as rough, scaly, skin-colored, erythematous or pigmented lesions of varying 
diameter (mm-cm) on sun-exposed skin areas. The differential diagnosis include cSCC, basal cell carcinoma 
(BCC), Bowens disease, seborrheic keratoses, stucco keratoses, lichenoid keratoses,  porokeratosis, arsenical 
keratoses, early keratoacanthoma, acantholytic acantoma, verruca vulgaris, acrokeratosis verruciformis, 
psoriasis, seborrheic dermatitis, lichen planus, discoid lupus erythematosus and in the case of pigmented 
lesions also lentigo maligna must be considered (Venna et al 2005, Lee et al 2014).  
Field cancerization defines a larger skin area where visible AKs are surrounded by early clinically 
undetectable changes with genetic oncogenic alterations spread over the sun-damaged field. Field 
cancerization involves a risk for multiple keratinocytic skin cancers (Braakhuis et al 2003, Braathen et al 
2012).  
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Figure 2. The skin cancer progression model: actinic keratoses (AK) represent the earliest clinically detectable phase in 
the continuum from sun-damaged skin towards invasive cutaneous squamous cell carcinoma (cSCC). Figure by Dr 
Giovanni Pellacani, edited with permission. 
1.2 Prevalence and incidence 
Non-melanoma skin cancers (NMSC) i.e. cSCC and BCC are the most common cancers in fair-skinned 
populations with an annual incidence of 3.5 million in the United States alone (Kozma et al 2014).  The 
majority of NMSCs are BCCs, but 20% are cSCCs that are capable of metastasing and causing death 
(Salasche 2000).  In Denmark, the age-standardized incidence rate for NMSC was 119/100 000 for men and 
117/100 000 in women in 2006-2010 (Bentzen et al 2013). Patients with multiple AKs but no previous 
NMSCs have very high risk of developing cSCCs (3,198/100000 person years) (Foote et al 2001). In Finland 
the age-standardize incidence of cSCCs is 96/100 000 person years (Finnish Cancer Registry statistics 
2011).  
AK prevalence (proportion of individuals with at least one AK in the population) is clearly associated with 
latitude ranging from 2.7% (16-70 yrs.)-11.5% (60-70 yrs.) in Germany (Schaefer et al 2014), to 5.9% in 
women and 15.4% in men over 40 years and 18.2% in women and 34.1% in men over 70 years in northern 
England (Memon et al 2000), to approx. 11-25% among adults in Ireland and northern USA (Frost et al 
1994),  to 50% (30-69 yrs.) in Australia (Frost et al 2000) with higher prevalences in men and increases with 
age in both sexes. In Austria, AK prevalence among dermatologic outpatients (≥30 yrs.) is as high as 31% 
(Eder et al 2014).  Previous AK dramatically increases the risk for further AKs. Annual incidence 
(proportion of individuals in the population who develop a new AK) was 84% in men and 69% in women 
with AK present at the baseline examination, and 15% in men and 7% in women without previous AK (Frost 
et al 2000).  In South Florida, the number of AKs treated by dermatologists was approx. 4500 per 100 000 
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per year in the population aged 0-65 years and approx. 110 000 per 100 000 per year in the population older 
than 65 (Nestor et al 2012). The incidence of AKs or carcinoma in situs is not registered in Finland. 
High incidence rates of AKs raise a significant economic issue. AKs tend to have high recurrence rates 
requiring repeated treatments and thus, multiple office visits (Warino et al 2006). In 2011 in Sweden the 
direct costs for AKs, including mostly the outpatient care, were 18 million euros accounting for over 10% of 
all the skin cancer costs (Eriksson et al 2014). In 2004 in the US the estimated total annual direct costs of 
AKs including office visits, drugs, hospital costs were 1.2 billion USD and indirect costs including lost 
workdays, restricted activity days and caregiver lost workdays were 295 million USD (Neidecker et al 2009).   
Etiology and risk factors 
The most important factor in NMSC development is solar UV radiation (UVR), absorbed by the keratinocyte 
DNA, which can act as a tumor initiator and promoter. The UVR spectrum contains UVC (200–290 nm), 
UVB (290–320 nm) and UVA (320–400 nm). UVC is mostly absorbed by the Earth’s ozone layer, Figure 3 
(D'Orazio et al 2013, Kozma et al 2014). Both UVB (290-320 nm), penetrating the superficial dermis, and 
UVA (320-400 nm) penetrating the deep dermis, can cause DNA damage leading to carcinogenesis. UVR 
can cause direct DNA-damage or indirect oxidative damage via reactive oxygen species (ROS). In addition, 
UVR causes immunosuppression by inducing immunosuppressive molecules and by affecting cells in the 
adaptive immune system (Chen et al 2013). UV-radiation also stimulates inflammation via cyclooxygenase 2 
(COX-2), a cascade which stimulates the proliferation of (pre)malignant keratinocytes (Maltusch et al 2011, 
Elmets et al 2014). AKs and cSCCs are caused by chronic cumulative UV-radiation while BCCs develop due 
to acute intermittent UV damage (Kraft et al 2014). 
 
Figure 3.  UVR penetration in the skin. From D'Orazio et al 2013, with permission. 
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In 1993, Campbell and colleagues found UV-induced mutations in the p53 tumor suppressor gene to be an 
early event in the development of cSCCs (Cockerell 2000, Heaphy et al 2000). The p53 gene, located in 
chromosome 17, regulates the cell cycle, DNA repair and apoptosis after DNA damage. Mutations in p53 
lead to impaired cell repair and resistance to apoptosis and thus, proliferation of mutant keratinocytes with 
elevated expression of mutated p53 protein (Holmes et al 2007, Kozma et al 2014).  Mutations in p53 occur 
in 50% of all human cancers, and in almost all carcinomas (Benjamin et al 2007). Mutations in p53 have 
been documented in 0-60% of AKs, in 15-96% of cSCCs, and also in chronically sun-exposed skin 
supporting the theory of a continuum from healthy skin through DNA-damage to AK, invasive cSCC, and 
finally potentially mortal metastasis (Callen et al 1997, Einspahr et al 1997). In addition, mutations of RAS 
(rat sarcoma) proto-oncogenes (HRAS, NRAS, KRAS) and of BRM tumor suppressor gene frequently occur 
in cSCCs (Kraft et al 2014, Chen et al 2013).  Recently also novel biomarkers including matrix 
metalloproteinases (MMP) have been found to be involved in the development of AKs and cSCCs (Kivisaari 
et al 2008, Kivisaari et al 2013, de Oliveira et al 2015). 
AKs serve as biomarkers for individuals at risk for the development of an invasive cSCC (Salasche 2000). 
Fair skin type (Fitzpatrick 1988), red or blonde hair, blue eyes, sunburns in childhood, solar lentigines, 
wrinkles and elastosis, freckles on the arms, old age, male sex, low educational level, outdoor occupation, 
residency in a tropical country, photosensitizing drugs (thiazile diuretics, amiodarone, diltiazem) increase the 
risk for AK (Traianou et al 2012, Schaefer et al 2014). Patients with solid organ transplantation and 
immunosuppressive medication (azathioprine, calcineurin inhibitors) have a 250 times as high risk for AK 
than do immunocompetent patients (Tessari et al 2012).  Dark skin protects against actinic damage due to its 
higher concentration of UV absorbing epidermal melanin (Holmes et al 2007). Some genetic syndromes such 
as albinism (lack of melanin), xeroderma pigmentosum (impaired DNA repair) and epidermodysplasia 
verruciformis (decreased cell-mediated immunity) increase the risk for AKs and cSCCs (Kraft et al 2014). 
Also patients with recessive dystrophic epidermolysis bullosa (RDEB) have increased risk for cSSC 
(Kivisaari et al 2008). Exposure to X-ray or psoralen ultra-violet A (PUVA) therapy induces the risk for AK 
(Zalaudek et al 2014). Also human papilloma virus (HPV) seems to play a role in the pathogenesis of AK 
and NMSC (Forslund et al 2003).  Chemical carcinogens like smoking and arsenic increase the risk for 
cSCC (Chen et al 2013). 
1.3 Histopathology and immunohistochemistry 
The diagnosis of AK is mainly clinical. Histopathological sampling is used in order to rule out invasive 
cSCC. The accuracy of clinical diagnosis of AK (positive predictive value) among dermatologists varies 
between 74% and 94% (Holmes et al 2007, Tschen et al 2006).   AKs representing induration or 
inflammation, diameter >1 cm, rapid enlargement, bleeding, erythema or ulceration should be considered for 
histopathological verification. Other characteristics arising suspicion of progression into cSCC include 
pigmentation, palpability, pain, pruritus and hyperkeratosis (Quaedvlieg et al 2006).  
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AK and cSCC are indistinguishable by cytology alone, and thus the histological diagnosis also requires 
architectural characteristics. Histological criteria for AK include pleomorphic atypical keratinocytes: nuclei 
that are hyperchromatic, an increased mitotic rate, and disordered maturation; an irregularly achantotic 
epidermis; irregular dermo-epidermal junction; and alternating hyperkeratosis, parakeratosis and 
orthokeratosis. Usually signs of photoaging: elastosis in the dermis, destruction of its fibrillar structure, and 
perivascular or lichenoid inflammation is present, Figure 4. AKs can be graded, analogously to cervical 
intraepithelial neoplasia, as grade I (mild, atypia of basal keratinocytes of the lower one third of the 
epidermis), grade II (intermediate; atypia of keratinocytes of at least the lower two thirds of the epidermis), 
and grade III (severe; diffuse atypical keratinocyte proliferation involving the full epidermal thickness) 
(Cockerell 2000, Tsatsou et al 2012). Histological variants of AK include pigmented, acantholytic, 
bowenoid, and hyperplastic AKs with a common characteristic of atypical keratinocytes confined to the 
epidermis (Tsatsou et al 2012).  Bowen’s disease is an intraepithelial cSCC defined by full-thickness severe 
squamous atypia, where the cells are in complete disorder (“windblown appearance”). Parakeratosis 
consisting of atypical cells is prominent. In conntrast to AKs, the atypical infiltrate replaces the epithelium of 
adnexal structures. When atypical keratinocytes invade basal membrane down to the dermis, forming lobules 
of atypical epithelium, the lesion is defined as invasive cSCC (Elder et al 2013).  
Sun-damaged skin includes dermal elastosis and atrophy, but only minor cytologic atypia, epidermal 
thickening and inflammation (Carpenter et al 2004). The skin adjacent to AKs often has many similar 
histological characteristics to an AK and has been suggested to represent very early AKs (Einspahr et al 
2014).  Early field cancerized areas represent genetically abnormal, but not yet histologically detectable, 
altered cells (Braakhuis et al 2003). 
Molecular markers, like p53, a marker for apoptosis and cell cycle arrest; and Ki67, a marker for cell 
proliferation, can be used in the detection of early carcinogesis. These markers are detectable before the 
occurrence of histologically detectable cellular changes, and increase as the carcinogenesis progresses 
(Carpenter et al 2004). In immunohistochemical stainings, p53 overexpression is seen as accumulated 
epidermal patches, Figure 4. Increased p53 expression, as an indicator of mutated p53, has been reported in 
0-80% of AKs and in 0-92% of cSCCs, but also in lower amounts in apparently normal sun-exposed skin. 
The variability of the methods used (frozen vs.fixed tissue) and antibodies explain the variability of the 
results. Some, but not all, immunohistochemical stainings distinguish between the mutant and wild-type p53 
protein (Einspahr et al 1997).  In addition, immunohistochemical markers for inflammation (COX-2, CD3, 
CD8), and angiogenesis (CD31) are also involved in the carcinogenic process (Maltusch et al 2011). 
Molecular markers can provide information about the mechanism of action and efficacy of the AK 
treatments (Einspahr et al 1997, Carpenter et al 2004, Maltusch et al 2011). 
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Figure 4, Grade II AK a) in HE-staining showing hyperkeratosis/parakeratosis, atypical keratinocytes in the lower two 
thirds of the epidermis and solar elatosis b) the same lesion with p53 immunostaining showing increased p53 
expression. Figure by Taneli Tani, MD, PhD, with permission. 
 
2. LENTIGO MALIGNA AND LENTIGO MALIGNA MELANOMA 
2.1 Definitions and clinical characteristics 
Lentigo maligna (LM) was first described by Hutchinson in 1912 as “the presence and overgrowth of 
atypical melanocytes at the dermal epidermal junction of chronically sun-damaged skin” (Bosbous et al 
2009).  Histologically, LM represents an in situ melanoma, which is limited to the epidermis and lacks 
dermal invasion. Lentigo maligna melanoma (LMM) represents the development of dermal invasion in an 
area of the LM (Bosbous et al 2009).  LMM is one of the four histologic subtypes of invasive malignant 
melanoma, the others being superficial spreading, nodular and acral lentiginous (Reed et al 2011). 
 Typical clinical presentation of LM and LMM include a brown-gray to dark colored black macule with 
poorly defined borders on sun exposed skin areas, typically on the head and neck. Size and color may vary 
and the lesions tend to slowly enlarge over time (Bosbous et al 2010). A rare amelanotic LM type may 
resemble eczema, Bowen’s disease or superficial BCC (Reed et al 2011).  Previous treatments may alter the 
appearance of LM and lead to misdiagnosis (Bosbous et al 2010). Clinically in situ LM and invasive LMM 
are hard to distinguish (Hazan et al 2008). The presence of increasing variation in color, border irregularity, 
expanding lesion size, regression or nodules may predict tumor invasion (McKenna et al 2006). It is also 
often difficult to clinically distinguish LM from benign lentigos, thin seborrheic keratoses and pigmented 
AKs. In addition, differential diagnosis includes cSCC, pigmented BCC and dysplastic nevus (Bosbous et al 
2010). LMs are characterized with a tendency to develop into subclinical peripheral disease, and an 
inadequacy of histological visualization leading to high recurrence rates (McKenna et al 2006). 
LMs represent a prolonged horizontal growth phase and thus their progression to invasion is slow. However, 
also rapid progression to LMM has been reported (McKenna et al 2006). The prognosis of invasive LMM is 
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similar to that of other types of invasive melanomas (Cox et al 1996, Kraft et al 2014).  The estimated 
lifetime risk for LM progression to invasive LMM varies between 5-50% with a higher risk associated with 
larger lesions (Bosbous et al 2010, Erickson et al 2010).  It should be noted that initial partial biopsies may 
not provide accurate histological diagnoses. In partial removal or punch biopsy, there is 8-29% risk that an 
invasive component will be missed (Kunishige et al 2012, Iorizzo et al 2013).Thus, excisional biopsy is the 
most accurate technique to diagnose LM and LMM. However, in the cases of large lesions, clinicians are 
often forced to use punch biopsies for diagnostic use (McLeod et al 2011).  
 LM and LMM have higher recurrence rates than other melanoma subtypes (Bosbous et al 2010). Twenty-
three percent of the initially inadequately excised LMs show an invasive component at the time of recurrence 
imposing the risk for metastatic disease. Furthermore, 33% of the recurrent primary LMMs appear at greater 
Breslow-thickness than the initial tumor (DeBloom et al 2010).  Thus, adequate initial removal of the lesions 
is crucial for the prognosis.  
2.2 Prevalence and incidence  
LM and LMM form the most common melanocytic malignancy of the head and neck regions (Bosbous et al 
2010). Worldwide LMM subtype represents 4-15% of all invasive melanomas while higher incidence is seen 
for superficial spreading melanoma and nodular melanoma (Swetter et al 2005, Youl et al 2013).   In 
California, LM is the most prevalent in situ subtype of melanoma (79-83%) and the incidence of both LM 
and LMM is rising above the other melanoma subtypes (Swetter et al 2005). Also in Sweden, LM is the most 
prevalent in situ melanoma subtype with age-standardized incidence of 1.29/100000 in men and 1.53/100000 
in women in 1993-98 (Hemminki et al 2003).In northern USA, age-and sex-adjusted LM incidence was 13.7 
per 100 000 person years in 2004-2007 with a 7-fold increase since 1970s and with the highest incidence in 
men between 70 and 79 years (91.3 per 100000 person years) (Mirzoyev et al 2014). In Denmark over a15-
year period between 1997 and 2011, LM incidence had markedly increased from 0.6 to 1.5 and from 0.5 
to1.4 cases per 100 000 person years in women and men, respectively (Toender et al 2014).  The increased 
incidence of in situ melanomas may partially be caused by a growing awareness of skin cancers and earlier 
removal of suspicious lesions (Toender et al 2014). 
There are no accurate costs data available for LM/LMM treatments.  Invasive malignant melanoma is the 
cost driver of skin cancers with over 90 million total annual costs accounting for over 50% of all the skin 
cancer costs in Sweden, while the annual costs for  in situ melanomas were only 1 million (0.6% of the total 
skin cancer costs) (Eriksson et al 2014). As the costs of the in situ disease are significantly lower than those 
of advanced or metastasized melanoma (Alexandrescu 2009), early detection and treatment are crucial. 
2.3 Etiology and risk factors 
UV-radiation induces increased melanin production and proliferation of melanocytes. UV-induced DNA 
damage leads to impaired cell cycle arrest and dysregulated proliferation of melanocytes (Reed et al 2011). 
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Unlike melanomas on the trunk, LMs are associated with NMSC and AK, markers of chronic UV-exposure, 
but not the number of nevi (Gaudy-Marqueste et al 2009, Kvaskoff et al 2013). In addition, BRAF mutations, 
commonly found in melanoma types associated with intermittent sun-exposure, are rare in LMMs 
(Maldonado et al 2003, Sasaki et al 2004, Stadelmeyer et al 2014). Familial risk for LM is low (Hemminki et 
al 2003).  Interestingly, p53 mutations, present in AKs and NMSCs, are commonly seen in LMMs (Purdue 
et al 2005). These facts support a theory that LMs have a distinct etiologic and genetic pathway i.e. “chronic 
sun-exposure pathway” compared to other melanoma types, which are associated with the “nevus pathway” 
and intermittent sun-exposure. Thus LMs are likely to originate from acquired mutations due to chronic sun-
damage on field cancerizated skin (Gaudy-Marqueste et al 2009, Kvaskoff et al 2013, Kraft et al 2014). In 
addition mutations in the KIT gene (encoding the stem cell factor receptor tyrosine kinase) may play a role in 
the pathogenesis of LM (Kraft et al 2014). In addition to chronic sun exposure, other risk factors for LM 
include fair skin type, low tanning ability, red or blonde hair, history of sunburns, and freckling at 
adolescence. LM risk increases in males and with old age (Mirzoyev et al 2014). The average age of which 
LM/LMM occurs is 66-72 years which is higher than that of other melanoma subtypes (45-57 years) 
(Bosbous et al 2010). Thus LMs are considered to be “late onset” melanomas (Kraft et al 2014). 
2.4 Histopathology and immunohistochemistry 
In situ melanomas, including LM, represent the earliest histologically detectable stage of malignant 
melanoma (Reed et al 2011). LMs are characterized by atypical junctional melanocytic overgrowth and 
underlying photo-damage. The histological characteristics of LM include atypical melanocytes at the dermal-
epidermal junction arranged in solitary units and small nests, pagetoid spread of atypical melanocytes, 
confluence of melanocytes replacing the basilar layer, solar elastosis, periadnexal extension of atypical 
melanocytes, epidermal atrophy and loss of the rete ridges, a dermal infiltrate composed of lymphocytes and 
melanophages and multinucleated melanocytes, Figure 5 (Flotte et al 1999).  LMM is defined when dermal 
invasion of atypical melanocytes is found (Tannous et al 2000). 
Some dermatopathologists regard LM as the initial phase of a more aggressive form of malignant melanoma 
in situ (MIS), LM type (Flotte et al 1999, Tannous et al 2000). Compared to LM, MIS LM type has 
additional features such as individual cells invading the upper epidermis (pagetoid spread) and confluent 
growth. However, this distinction is rarely used in the literature and the treatment for LM and MIS LM type 
is similar. 
Histological different diagnoses of LM include pigmented AK, seborrheic keratosis, pigmented BCC, 
porocarcinoma, pigmented epidermotrophic metastases and Paget’s disease (Wiltz et al 2007). In parts of LM 
also benign lesions may be present, and thus partial biopsies may lead to sampling error and misdiagnosis 
(Dalton et al 2005). 
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The presence of LM on the sun-damaged skin poses a diagnostic challenge to dermatopathologists (Reed et 
al 2011, Acker et al 1998). The diffuse melanocytic overgrowth of sun-damaged skin makes it challenging to 
assess the peripheral margins of LM. Also benign melanocytes may extend along the hair follicles (Hendi et 
al 2006). The margin may also be obscured by benign lentigos, seborrheic keratoses and AKs (Dalton et al 
2005). Morphometric analyses of melanocytes may help identify LM margins from sun-damaged skin. 
However, section artifacts and nuclear shrinking in formalin-fixed material are problematic (Acker et al 
1998). 
It is common that LMs continue histologically several mms to cms beyond the clinically defined border 
(Breuninger et al 1999). The goal of the surgery is “negative margins”.  “Positive or involved margins” are 
reported when histologic features of LM extend to the periphery of an excised specimen. The distance 
between specimen border and nearest histological findings of LM is called the histological margin (Hazan et 
al 2008). It should be noted that the guidelines for lesion removal are based on clinically measured margins 
and that the histological margins differ from those assessed clinically because of the shrinking of paraffin 
embeded specimens. 
Several immunostains can be used to help detection of LM.  Melanoma antigen recognized by T-cells 
(MART-1, also named Mel-A) is a cytoplasmic melanosome-associated transmembrane glycoprotein 
expressed by benign and malignant melanocytes, Figure 5. It is considered as the most sensitive marker for 
melanoma (McLeod et al 2011). However, also normal sun chronically sun-exposed skin contains high 
numbers of MART-1 positive melanocytes (Hendi et al 2006).   Also pigmented AKs, which can occur in the 
vicinity of LMs, stain positively with MART-1 which may be misleading for positive margins (El Shabrawi-
Caelen et al 2004). However, in a more recent study MART-1 with azure-B counterstaining was successfully 
used to differentiate LM from pigmented AKs (Wiltz et al 2007). S-100 is a calcium-binding protein present 
in melanoma cells, but also in various benign cells. Thus it has a low specificity and it is not widely used for 
LM detection (Erickson et al 2010). Human melanoma black (HMB-45) is a murine monoclonal antibody 
binding to melanosome-associated sialated glycoprotein (gp100) present in neoplastic, fetal and immature 
active melanocytes. HMB-45 is not widely used due to its poor sensitivity compared to other 
immunostainings (McLeod et al 2011). Mel-5 is a murin monoclonal antibody that binds glycoprotein75 in 
mature melanocytes. It stains epidermal and basal melanocytes and can be used in the detection of LM 
borders, but it is not suitable for the detection of invasive LMM (McLeod et al 2011). In addition, 
micropthalmic transcription factor (MITF), a nuclear stain may be useful in LM margin detection (McLeod 
et al 2011). 
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Figure 5 a) LM HE-staining showing atypical junctional melanocytes and nevoid nests, solar elastosis and b) LM 
immunostaining (MART-1) showing atypical junctional melanosytic proliferation and periadnexal extension, c) LMM 
Breslow 1.1 mm HE-staining showing epidermal characteristics of and LM and atypical melanocytic proliferation into 
the dermis, c) LMM Breslow 1.1 in MART-1/Melan A-staining shoving melanosytic proliferation in dermo-epidermal 
junction and into the dermis. Figure by Leila Jeskanen, MD, with permission. 
 
3.  NON-INVASIVE METHODS FOR SKIN CANCER DETECTION 
 
Figure 6. Light reflectance from the skin. Figure by Ilkka Pölönen, PhD, with permission. 
Despite being the gold standard of cancer diagnosis, histopathology has its limitations. First of all, the 
processing of the samples is time consuming.The numerous and sometimes unnecessary invasive biopsies 
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can be burden to a patient. Additionally, the histological cross-sectional processing of the samples enables 
detection of only a tiny (approx.1%) part of the specimen (Bosbous et al 2010). The diagnosis is greatly 
dependent on the judgment of the pathologists (Akbari et al 2011). Typically patients have multiple lesions 
that are widespread on sun-damaged skin areas and visual inspection fails to detect the earliest changes. Non-
invasive imaging techniques have emerged to aid clinical diagnosis and assessment of the early invisible 
changes and thus enable more accurate primary treatment and follow-up. 
When it reaches the skin surface, some of light is reflected or scattered back while some light is absorbed 
and only a small percentage of the incident light penetrates deeper structures. The energy from the absorbed 
light activates specific fluorophores in the skin to emit fluorescence when returning back to rest stage 
(Szepetiuk et al 2011).Thus, by monitoring lights behavior in the skin,  it is possible to obtain insights into 
the skin’s structures, Figure 6. 
Various novel non-invasive imaging methods are based on either the detection of light reflectance, scattering 
or emitting (fluorescence) in the skin (Calin et al 2013). The commercially available devices are listed in 
Table 1. The devices can be classified according to their resolution as follows: 1) primary; detects 
subcellular structures (melanosome, melanin, nucleioli), 2) secondary; detects at cellular resolution 
(melanocytes, keratinocytes), 3) tertiary; detects cellular aggregates (cell nests, collagen, and blood vessels), 
4) quaternary; detects characteristics visible to the naked eye (Marghoob et al 2003). In addition this chapter 
introduces the principle of hyperspectral imaging.  This novel method is not yet commercially available for 
skin cancer detection. 
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Table 1.Commercially available devices for detection of premalignancies the photodamaged skin including actinic 
keratoses (AK) and lentigo malignas (LM). FOV=field of view. 
3.1 Fluorescence detection 
Fluorescence detection can be based either on the detection of natural fluorophores of the skin (e.g. elastin, 
collagen, melanin) (Andersson-Engels et al 1991, Brancaleon et al 2001), or the detection of fluorescence 
caused by exogenous fluorophores (Tyrrell et al 20101, Calin et al 2013). 
Protoporphyrin IX (PpIX) exhibits red fluorescence when excited with blue light matching the 410 nm 
absorbance peak (Tyrrell et al 20101).  Fluorescence-based photo detection (PD) can be used to detect the 
areas of high PpIX accumulation corresponding to tissue with a high degree of dysplasia, and thus the 
detection of the field cancerized skin (Ericson et al 2004), Figure 7. Fluorescence detection can be 
performed either by fluorescence imaging or fluorescence spectroscopy (Calin et al 2013). Several non-
invasive devices like Wood’s light (Philips Burton®, Somerset, USA) (Fritsch et al 1998, Passos et al 2013) 
, CCD fluorescence camera systems (i.e. Dyaderm®, Biocam GmbH, Regensburg Germany; Medeikonos® 
PDD/PDT, Medeikonos AB, Gothenburg, Sweden; Visioscan® VC98 and Visiopor® PP34, C+K 
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electronics, Cologne Germany) (Tyrrell et al 20101, Wiegell et al 2008, Szepetiuk et al 2011), fluorescence 
spectroscopy devices (Hewett et al 2001, Juzeniene et al 2006), as well as invasive fluorescence microscopy 
(Dögnitz et al 2008) can be used in the detection of PpIX fluorescence. Some devices like Wood’s light 
provide subjective information while validated systems like CCD cameras can provide semi-quantitative 
information. PD can be used in the detection of areas in need of treatment, and to help manage the post-
treatment follow-up (Liutkeviciute-Navickiene et al 2009). PpIX is the main component in porphyrin-based 
photodynamic therapy (PDT) and thus PD can be used to monitor the treatment effect (Ericson et al 2004). 
The intensity of the fluorescence can provide information on the selectivity of the photosensitizer (Martin A 
et al 1995, Fritsch et al 1998).  Photobleaching i.e. photo-oxidation of the photosensitizer seen as diminished 
fluorescence intensity during PDT, indicates the level of cellular damage, and thus is predictive for treatment 
efficacy. Over 50-60% reduction in fluorescence intensity during treatment predicts complete clearance.  In 
contrast, the intensity of total initial PpIX fluorescence alone fails to predict the treatment efficacy (Tyrrell et 
al 20102).  In daylight-photodynamic therapy (DL-PDT), PpIX is activated during its development, leading 
to low PpIX-fluorescence levels and no photobleaching (Wiegell et al 2008).  There are several limitations in 
PD. The exogenous fluorescence detection procedure is time-consuming, due to hours of PpIX precursor 
application followed by imaging, and thus is not useful for daily clinical practices (van der Beek et al 2012). 
Although highly accumulated in cancerous tissues, also non-cancerous skin diseases like psoriasis 
accumulate PpIX (Smits et al 2005).  In addition, PD is not useful in monitoring the progression of 
carcinogenesis as it fails to distinguish between between AKs and invasive cSCC (Kleinpenning et al 2010).   
A UV lamp, Wood’s light (320-400 nm, peak 365 nm), first described in the beginning of the 1900s, is also 
commonly used in the detection of ill-defined borders of LM/LMM in order to achieve more accurate 
primary excision margins. Melanin absorbs the majority of the UV radiation the skin is exposed to. Thus, in 
Wood’s light examination, areas with increased amounts of epidermal melanin appear darker than the 
surrounding skin which in some cases may help define peripheral subclinical melanocytes, Figure 7 
(Robinson JK 2004, Paraskevas et al 2005, Kimyai-Asadi et al 2007, Hazan et al 2008).  
27 
 
 
Figure 7 a) Field cancerization in Wood’s light (PpIX fluorescence), b) lentigo maligna in Wood’s light. Figures by 
Noora Neittaanmäki-Perttu with the permission of the patients. 
3.2 Dermatoscopy 
Dermatoscopy (i.e. epiluminescence microscopy, Dermlite® 3GenCA, USA, Molemax®, Derma 
Instruments Vienna Austria), using transilluminating or polarized light, provides x10 to x30 magnified 
images of the structures in epidermis and papillary dermis. Dermatoscopy was initially developed to aid 
melanoma diagnosis, but has also been introduced as a diagnostic tool for non-melanoma skin cancers 
(Fargnoli et al 2012). Dermatoscopy can be used in the detection of AKs (Huerta-Brogeras et al 2012) as 
well as in the detection of LM borders (Robinson JK 2004).  
Dermatoscopy can aid AK diagnosis with a sensitivity of 98.7% and specificity of 95% (Huerta-Brogeras et 
al 2012). However, the technique is based on morphologic features and is strongly user-dependent. 
Dermatoscopic criteria for AK include a pink-to red erythematous pseudonetwork, surface scale, follicular 
openings filled with keratotic plugs, vascular structures including linear-wavy vessels or coiled/dotted 
vessels around the hair follicles. Dermatoscopically AKs can be divided into three different grades: grade I 
red pseudonetwork, discrete white scales; grade II erythematous background, white to yellow keratotic 
enlarged follicular openings (strawberry sign); grade III white-yellow background with enlarged follicular 
openings filled with keratotic plugs, or white-yellow structureless areas due to marked hyperkeratosis, 
Figure 8. The presence of advanced vascular structures (dotted, glomerular, hairpin or linear vessels) is a 
sign of more aggressive growth preceding SCC development (Zalaudek et al 2014).Hyperkeratotic AK have 
a light-pink-to-yellowish hue without visualization of the underlying structures. Pigmented AKs are seen as 
gray-to-black dots and globules around the follicular openings, annular granular structures, brown-to-gray 
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pseudo network, and rhomboidal structures, some of the dermatoscopic characteristics overlapping with 
those of lentigo maligna. Other differential diagnosis include Bowens disease with glomerular, irregular, 
linear or dotted vessels in small clusters, and a scaly surface; cSCC showing polymorphous vascular 
structures including glomerular “hairpin”, dotted, linear or irregular vessels, white structure less areas, 
central keratin mass and ulceration; BCC showing arborizing vessels, ulceration, blue-gray globules, ovoid 
nests, leaf-like and spoke wheel areas; sebaceous hyperplasia showing crown vessels (Huerta-Brogeras et al 
2012, Fargnoli et al 2012). Dermatoscopy has been used to monitor the treatment efficacy and for the 
diagnosis of recurrent lesions (Kaçar et al 2012). However, only limited histologically confirmed evidence is 
available and it is unclear whether dermatocopy is able to detect subclinical lesions. In one study, despite the 
complete histological clearance of 33/34 lesions only 15/34 lesions showed complete disappearance in 
dermatoscopy.  The authors claim that the disappearance of even one dermatoscopic sign of an AK predicts 
its clearance (Lee et al 2014). 
Dermatoscopy has also been used for the detection of LM and delineation of the borders pre-surgically. LM 
on the face do not show the classical dermatoscopic features found on the other parts of the skin due to 
atrophic epidermis and pseudonetwork caused by follicular openings and sweat glands. Thus, on the face it is 
difficult to distinguish between melanocytic lesions from non-melanocytic lesions like seborrheic keratoses 
or pigmented AKs (Stolz et al 2002). The specific dermatoscopic criteria for facial LM are: a variating 
number of colors, asymmetric hyperpigmented follicular openings, fine grey dots and globules around the 
follicles (annular granular pattern) and an enhanced vascular network, Figure 8. In invasive forms (LMM) 
pigmentation might be rhomboidal or obliterate the hair follicles (structureless area), the variation of colors 
is greater than in LM, in addition rhomboidal vascularity and ulceration might be present, Figure 9. In 
addition, darkening in the dermatoscopic examination is indicative of the condition (Stolz et al 2002, Pralong 
et al 2012). A sensitivity of 89% and spesificity of 96% have been reported for the combination of 4 
dermatoscopic criteria: 1) asymmetrical follicular openings (indicating uneven descent of melanoma cells 
within hair follicles), 2) dark rhomboidal structures (due to cohesive sheets of melanoma cells in the 
epidermis and upper dermis), 3) gray globules, 4) gray dots (both indicating melanin-loaded macrophages in 
the upper dermis) of the LM (Schiffner et al 2000).  It has been shown that dermatoscopy detects lesion 
borders more accurately compared to clinical assessment and assessment with Wood’s light (Robinson 
2004). There are also automated analysis methods for the lesion border delineation in digital dermatoscopy 
images (Abbas et al 2011). However, the methods use visible lesion borders as a standard and thus are not 
useful in the detection of subclinical LM borders. 
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Figure 8.a) Dermatoscopic image of an AK (grade I) showing a red pseudonetwork and discrete white scales, b) 
Dermatoscopic image of LM showing varieting colors, asymmetric hyperpigmented follicular openings and dark 
rhomboidal structures. Figures by Noora Neittaanmäki-Perttu with the permission of the patients. 
 
 Figure 9. Dermatoscopic criteria, progression model from LM to LMM. a) Dots aggregated around hair follicle, short 
streaks, asymmetric follicular openings, subtle annular-granular pattern b) annular-granular pattern clearly visible, 
rhomboidal structures, melanoma cells within the follicle proliferate and invade adjacent dermis, c) homogenous areas, 
hair follicles spared, d) homogenous areas, hair follicles obliterated, development of milky red areas (invasive 
melanoma).  Edited from Stolz et al 2002 with the permission of Elsevier. 
3.3 Reflectance confocal microscopy 
The reflectance confocal microscopy (RCM, VivaScope®, MAVIG GmbH, Lucid Inc.) technique is based 
on laser scanning microscopy, which unlike conventional microscopes in which thin tissue sections are 
illuminated from below, illuminates skin surface from above with a focused laser (coherent 700/2500 nm)  
and collects the reflected and scattered light. Images can be obtained in vivo from the skin surface or from 
excised tissue sections.  RCM provides a nearly-histologic resolution (0.5-1μm laterally and 3-5 μm axially) 
gray-scale (black and white) horizontal (en-face) image of the cellular and subcellular structures in the 
epidermis and papillary dermis up to a depth of 350 μm (Horn et al 2008, Ulrich M et al 2010). In the RCM 
images the melanocytes’ cytoplasm appears intensely white while the keratinocytes reflect less of the laser’s 
light and thus appear darker. Cell nuclei appear dark and collagen very bright (Carrera et al 2012).Some 
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devices combine dermatoscopy to guide RCM imaging (Vivacam®, Mavig). The field of view (FOV) of a 
single image is small 500 x 500μm, but by using composite images up to 8x8 mm skin areas can be obtained. 
The small FOV and imaging at several layers leads to a relatively slow imaging process (5 min for 8x8 mm2 
one hour for a whole cheek) and thus the technique is not very suitable for the mapping of wide areas in daily 
practices. The overall sensitivity and specificity of RCM are high, 90.8% and 77.5%, respectively (Horn et al 
2008).It’s large inter observer variations indicate that the device is strongly user-dependent (Ulrich M et al 
2010). Furthermore, the device is expensive (approx. 160 000 euros according to the company MAVIG) and 
costs of RCM are not reimbursed (Guitera et al 2013).  
In RCM, AK characteristics include parakeratosis/hyperkeratosis, irregular stratum corneum and irregular 
epidermal architecture (“honeycomb pattern”), atypical keratinocytes (nuclear and cellular pleomorphism). 
Also spongiosis, solar elastosis, increased vascularity/blood vessel dilatation and superficial inflammatory 
infiltrate can be present, Figure 10 (Ulrich M et al 2010). Grade I AKs present as focal areas of atypical 
keratinocytes can be seen as irregular honeycomb patterns only at the level of the stratum spinosum, whereas 
in grade II AKs areas of markedly atypical keratinocytes with varying sizes and shapes, are more diffuse and 
involve both the stratum spinosum and granulosum. Grade III AK presents itself as markedly atypical 
honeycomb patterns with partial disruption of the normal epidermal layers (Zalaudek et al 2014). The 
cellular atypia, architectural disruption in stratum spinosum and solar elastosis can be visualized before their 
clinical appearance, and serve as markers of subclinical AKs. RCM can also be efficiently used for 
monitoring the treatment response (Ulrich M et al 2010, Malvehy et al 2014). The morphologic findings in 
the skin detected with RCM correlate well with the findings in invasive histopathological examination 
(Longo et al 2013, Malvehy et al 2014), Table 3. 
RMC can be used to differentiate between benign and malignant melanocytic lesions. However, the imaging 
depth is limited to the epidermis, and thus RCM fails to detect the thicker invasive components of tumors 
(Carrera et al 2012). The special characteristics of LM (“the LM score”) in RCM include major features (2 
points): nonedged papillae and round pagetoid   large cells; and minor features (one point):  nucleated cells 
in the dermal papilla, three or more atypical cells at the dermoepidermal junction in five 0.5x0.5mm2 images, 
follicular localization of pagetoid cells and/or atypical junctional cells; and a single “negative” (benign) 
feature (-1 point) of broadened honeycomb pattern of the epidermis, Figure 11, Table 2. The sensitivity and 
specificity of these criteria (≥2 points) for differentiation of LM from benign pigmented facial macules by 
RCM were 85% and 76%, respectively. Some of the RCM features are present in both LM and benign 
pigmented lesions e.g. pigmented keratinocytes may have similar reflectance signal as that of melanocytes, 
which may be confusing (Guitera et al 2010).  RCM is useful in the detection of LM borders. RCM revealed 
subclinical continuum, not detected dermatoscopically, in 17 of 29 (59%) LMs and it was suggested that 
RCM might be more valuable than routine histology (Guitera et al 2013). RCM may be used in monitoring 
the efficacy of non-invasive treatments of LM (Alarcon et al 2014). 
31 
 
 
Figure 10 a) Dermastocopic image of an AK (grade II) showing an erythematous background and yellow keratotic 
enlarged follicular openings, b) Confocal microscopy image of AK (grade II) showing a pleomorphic epidermis. In the 
granular layer a destroyed honeycomb pattern with atypical keratinocytes is visible. Figure by Dr. Martina Ulrich, with 
permission of MAVIG. 
 
Figure 11.Diagnostisc of lentigo maligna melanoma (LMM) in the face with confocal microscopy. a) a clinical 
photograph, b) the dermatoscopic examination shows a darker area in the center of the lesion and rhomboidal structures, 
c-d) the images representing confocal microscopy: c) the composite image allows an overview of the lesion and the 
total architecture, d) in the single images (1mmx1mm) the cells are visible, e) single malignant pigmented cells can be 
detected (red arrows) allowing the immediate diagnosis of LMM. Figure by Dr Martina Ulrich with permission. 
32 
 
 
Table 2. Correlation of LM characteristics in histology, dermatoscopy and RCM. 
3.4 Optical coherence tomography 
Optical coherence tomography (OCT) (Vivosight OCT, Michelson Diagnostics Ltd) resembles ultrasound 
but uses back-scattered infrared-light waves instead of sound waves. OCT provides cross-section images 
with higher resolution than ultrasound (7μm laterally and 10 μm axially) to depths of 2 mm (deep dermis). 
FOV is 6x6 mm. In OCT, AKs are seen as disrupted epidermal layering, thickened epidermis, whites 
strikes/scales are seen in cases of hyperkeratosis (Banzhaf et al 2014), Figure 12. OCT can be used to 
monitor effects of the treatment procedures (Themstrup et al 2012), and treatment efficacy (Banzhaf et al 
2014, Themstrup et al 2014).  In conventional OCT image artifacts are common: inflammation, thick 
hyperkeratosis or ulceration blur the image and lower the image quality (Mogensen et al 2009, Banzhaf et al 
2014). The OCT procedure is time-consuming and due to its low resolution AK visualization is poor (Maier 
et al 2013). The sensitivity and specificity for distinguishing AK from normal skin is dependent on the 
observers’ skills varying between 58-94% and 43-96% respectively (Mogensen et al 2009). When using a 
computer-assisted analysis to detect the presence of a dark band as a sign of AK in OCT-images, a sensitivity 
of 86% and specificity of 83% were attained (Korde et al 2007). In OCT, different tumor types (AK, BCC, 
benign lesions) are indistinguishable and the naked eye was more accurate in diagnosing NMSC (Mogensen 
et al 2009).   
More advanced high-definition optical coherence tomography (HD-OCT, Skintell®, Afga Healthcare) 
reaches up to 570 μm depth, i.e. includes thickness of the whole epidermis and superficial dermis, and unlike 
conventional OCT, provides both horizontal (en face), vertical cross-sectional (slice) images with improved 
3-μm resolution. FOV is 1.8 x 1.5 mm. In horizontal imaging AKs are characterized by hyperkeratosis and 
parakeratosis, disruption of the stratum corneum, cellular/nuclear polymorphism, solar elastosis, perivascular 
inflammation, and architectural disarray which is seen as atypical honeycomb patterns presenting in the 
lower 1/3 of the epidermis in grade I AKs, and the lower 2/3 in grade II AKs and throughout the epidermis in 
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grade II AKs in great correlation with histopathologic evaluation.  Signs of AK in vertical imaging are 
similar than in conventional OCT. Also subclinical AKs are detectable with HD-OCT (Boone et al 2013, 
Maier et al 2013). The characteristics of different grades of AKs in OCT, RCM, dermatoscopy and histology 
are shown in Table 3. 
OCT is also used in presurgical margin assessment for non-melanoma skin cancers (Alawi et al 2013). Due 
to the poor resolution and visualization of the melanocytes, OCT is rarely used in the detection of pigmented 
lesions (de Giorgi et al 2005) and is not yet used for delineation of LMs. HD-OCT could probably be used in 
LM delineation, but no data of this apparently exists. 
 
Figure 12.OCT images (Vivosight OCT, Michelson Diagnostics Ltd), a) normal skin on the lower lip: Normal layering, 
clearly defined dermo-epidermal junction. The hyporeflective streaks in the dermis are vessels. The image depth is 0.98 
mm.  b) AK on the lower lip: Disrupted layering, thickening of the epidermis, the dermo-epidermal junction is not 
clearly defined. There are no visible basal cell nests. AK's sometime display white streaks in the epidermis, but they are 
not evident in this image. The lesion image depth is 1.0 mm and it is 4.8 mm wide. Figure by Lotte Themstrup, MD, 
with permission. 
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Table 3. Correlation of the findings of different AK grades in OCT, RCM, dermatoscopy and histology 
3.5 Raman spectroscopy 
The term spectroscopy means detection of how light uniquely reflects, absorbs, emits and scatters at different 
wavelengths from different substances based on their molecular composition. 
Raman spectroscopy detects the scattered energy of molecular vibrations of tissue biomolecules due to laser 
light (785nm) excitation. Different vibrational energies, seen in Raman spectral peaks, correspond to 
different chemical compositions, specific molecular structures (lipids, proteins), and molecular interactions 
and allows us to distinguish between malignant and benign tissues (Gniadecka et al 1997, Choo-Smith et al 
2002). Tissues related histogenetically, like AKs and cSCCs, provide similar spectral signals (Gniadecka et 
al 1997). The complexity of the spectra requires automated computer assisted classification algorithms. The 
technique provides information on whether the detected spot is suspected to be malignant or benign. No 
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image is provided. In a multicenter study in which the Raman spectra of 518 lesions, including AKs (n=32), 
LMs (n=20) and LMMs (n=8), the sensitivity of 90%, specificity of 67% was shown for distinguishing 
malignant from benign skin lesions (Lui et al 2012). A limitation in this study was that only 20-42% of the 
lesions suspected to be premalignant or benign were verified by histopathology, Figure 13. Due to small 
FOV (3.5 mm diameter) and that the device fails to provide images the method is not used for delineation of 
lesion borders. Another disadvantage is the limited detection depth of 200 μm. 
 
Figure 13. Raman spectral peaks for malignant and benign skin lesions. Lui et al 2012 with permission from the 
American Association for Cancer Research. 
3.6 Multispectral imaging 
In multispectral imaging sequences of images (5-15) are taken at different non-continuous narrow bands of 
wavelengths (Marghoob et al 2003). Two devices are commercially available for multispectral skin 
detection: spectrophotometric intracutanues analysis, SiaScope (Astron Clinica, Cambridge, UK) and 
Melafind (Mela Sciences Inc., Irwington, New York, USA). The difference between these two devices is that 
Melafind provides an automated computer-assisted diagnosis, while Siascope provides graphs and images 
(SiaGraphs) for the physician to interpret (Marghoob et al 2003). FOVs are 12x12mm -24x24 mm and 
22x22 mm, imaging depths 2 mm and, and resolutions 50-100 μm and 20μm for SiaScope and MelaFind, 
respectively. Siascope uses five to eight and Melafind ten different narrow bands of wavelengths ranging 
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from blue visible light to the near infrared (approx. 400-1000 nm). Both SiaScope and Melafind also provide 
dermatoscopic images. 
Acquired siagraphic images represent the concentration, distribution, and position of skin choromophores 
(melanin, hemoglobin, and collagen) in different skin layers. Siascopy was initially developed for the 
diagnosis of melanoma (Moncrieff et al 2002), Figure 14. In addition, Siascope has been used for the 
detection of different chromophoresin sun-damaged skin and found an increase in the amounts of melanin 
and a decrease in amounts of collagen due to sun damage and aging (Stimpfle et al 2014).  In a study 
assessing the sensitivity and specificity of Siascopy, great inter-observer variability have been observed and 
dermatoscopy was more specific in aiding diagnosis of NMSC including AKs (Hacioglu et al 2013).  As far 
as we know Siascopy has not been used for delineation of LM borders, which clearly could be an indication 
of the effectiveness of this device even though the FOV is limited to a diameter of 2 cm.  
 
Figure 14. Siagraphs of superficial spreading melanoma Breslow 2.5 mm. From Moncrieff et al 2002 with permission 
from John Wiley and Sons. 
Melafind provides binary automated analysis of the imaged lesion indicating whether the lesion should be 
biopsied to rule out melanoma, or not.  The sensitivity is high (98.4%) but the specificity is low (9.9%) 
(Monheit et al 2011). To our knowledge Melafind has not been used for delineation of presurgical margins, 
or in detection of AKs or NMSCs. 
3.7 Principle of hyperspectral imaging 
Hyperspectral imaging i.e. “imaging spectroscopy” differs from other spectroscopy techniques in that the 
spectral data can be obtained from an image (Harris 2006).  The technique  combines the advantages of 
digital imaging and spectroscopy , delivering information  that is beyond the level detectable by the human 
eye including subtle wavelength differences and certain wavelengths (infrared, ultraviolet) which are outside 
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the range of human vision (Panasyuk et al 2007, Liu et al 2012) . A regular camera captures images in three 
broad wavebands (red, green, blue) while a hyperspectral camera uses tens to hundreds of continuous narrow 
wave bands of light delivered from a tunable filter. In addition to filters also prisms can be used (Chang 
2007). In comparison the term multispectral imaging refers to use of multiple (4-15) wider, non-continuous 
bands of wavelengths resulting in discrete spectral images (Dicker et al 2006, Jolivot et al 2011).  A 
hyperspectral image is a composite image consisting of tens to hundreds of overlapping images, of which 
each image is taken at a different wavelength. Each pixel in the hyperspectral image has its own spectral 
signature which represents the optical characteristics of each imaged spot at different wavelengths. Thus, in 
addition to spatial (x, y location) information, hyperspectral image contains a spectral graph (z intensity) for 
each pixel, Figure 15 (Martin ME et al 20061). A hyperspectral imager can either detect diffuse reflectance 
or fluorescence at different wavelengths of light (Martin ME et al 20062). Different biological tissues can 
rapidly be identified from their unique reflected spectral signatures which provide information on their 
biochemical characteristics (Siddiqi et al 2008, Panasyuk et al 2007).  Diffuse reflectance records both light 
absorption and scattering and thus provides information on tissue morphology and chromophore content 
(Calin et al 2013, Zonios et al 2001).  The tissue choromophores recorded by diffuse reflectance include: 
oxyhemoglobin, deoxyhemoglobin, bilirubin, methemoglobin, melanin and water (Zonios et al 2001, 
Panasyuk et al 2007). Thus, hyperspectral reflectance imaging of the skin can provide information about the 
thickness of the skin layers, blood volume, oxygenation, and melanin concentration (Yudovsky et al 2010).  
Since hyperspectral imaging was first developed for satellite earth investigations (Harris 2006), it has been 
studied for several medical microscopic and in vivo macroscopic applications. Hyperspectral imaging has 
been used  in animal cancer models for detection of residual breast tumors during surgery in rats (Panasyuk 
et al 2007) and the detection of  rat oral cancer in sectioned tissue (Fixler et al 2014).  Human 
cytological/histopathological studies show that microscopic hyperspectral imaging  has some potential in the 
differentiation of (pre)cancerous cervix cells from healthy cells (Siddiqi et al 2008), melanoma detection and 
classification of spitzoid lesions on histological slides (Dicker et al 2006, Gaudi et al 2014).  In vivo studies 
in humans show potential in the detection of tongue tumors (Liu et al 2012) and gastric cancer (Akbari et al 
2011). Hyperspectral imaging has also been suggested to have potential in prostate cancer screening in 
humans (Manyak et al 2006). Some pilot studies of hyperspectral imaging of the skin in vivo include 
detection of the microcirculation of the skin surrounding diabetic wounds to predict healing (Yudovsky et al 
2010) , in vivo melanoma detection (Nagaoka et al 2012) and in vivo assessment of  melanoma response to 
chemotherapy (Dicker et al 2011). These studies show that hyperspectral imaging has some potential in the 
detection of cancer, delineation of tumor margins and assessment of treatment efficacy.  As far as we know, 
no previous hyperspectral data are available for non-melanoma skin cancer or actinic keratoses or the 
detection of LM borders. The high costs of the hyperspectral sensor and computational complexity are the 
main reasons why hyperspectral imagers are not yet widely used in medical applications. However, recently 
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improvements in computers and the development of novel mathematical algorithms have been combined in 
attempts to overcome this problem (Pölönen 2013). 
 
Figure 15. The principle of the hyperspectral image. A hyperspectral image is a composite image consisting of tens to 
hundreds of overlapping images, with each image taken at a different wavelength. Thus every pixel has its own spectral 
signature. Figure by Ilkka Pölönen, PhD, with permission. 
4. TREATMENT OF ACTINIC KERATOSES AND FIELD CANCERIZATION 
4.1 Why treat actinic keratoses? 
Even though AKs may spontaneously regress over time, the inability to predict which lesion will regress and 
which will develop into an invasive cSCC makes it important to treat all AKs. In addition, AKs that regress 
also commonly recur (Werner et al 2013).   The risk for a single AK developing into cSCC has been 
estimated to range between 0.025% and 20% per year (Quaedvlieg et al 2006).  Based on this it was 
calculated that for patients with multiple AKs, the annual risk for developing cSCC would range between 
0.15% and 80% (Stockfleth 2012). Only a few prospective longitudinal studies that have assessed the true 
transformation rates and reported the risk to be as low as 0.075% per lesion per year for patients with no 
previous NMSC and 0.53% per lesion per year for patients with previous NMSC (Marks et al 1988, 
Criscione et al 2009).  However, even if the annual risk for a single lesion transfering is low, the risk for a 
patient with several lesions over a course of several years, increases the possibility for cSCC significantly 
(Dodson et al 1991). Although, here are some signs for “high risk AKs”, invasion can not be predicted 
clinically (Quaedvlieg et al 2006). Clinically 60-65% of cSCCs progress to the areas of previous diagnosed 
AKs, and the rest develop in apparently healthy skin (Marks et al 1988, Criscione et al 2009).  Histologically 
72-82% of cSCCs arise contiguously with AKs (Mittelbronn et al 1998, Czarnecki et al 2002). The 
progression from AK to cSCC has been estimated to be 2 years (Fuchs et al 2007). Thus, treatment of AKs 
and surrounding cancerized field can be considered as secondary prevention for cSCCs (Ceilley et al 2013).  
Reported spontaneous regression rates  for single lesions vary greatly from 18% over 7 months, 25.9-74% 
over one year, and 70% over 5 years (Marks et al 1986, Thompson et al 1993, Frost et al 2000, Criscione et 
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al 2009). A recent review evaluated the lesion regression rate of 15-63% after one year (Werner et al 2013). 
However, of these regressed lesions 15%-53% recurred within a year (Werner et al 2013). The regression of 
the complete field is rare (0-21%) with up to 75% recurrence (Werner et al 2013). This is in concordance 
with the finding that AKs appear as a continual flux and despite the regression, the number of AKs increase 
over time (Marks et al 1986). 
There are also other facts that support the treatment of AKs. AKs are the most prevalent cancer precursors in 
humans (Quaedvlieg et al 2006). The treatment of similar precursors in other organs (like the cervix) is 
widely accepted (Soergel et al 2012).In addition patients also suffer from symptoms of AKs on cosmetically 
sensitive areas. As 25-75% of AK patients require repeated treatments, AKs should be treated as a chronic 
disease (Ceilley et al 2013). Thus, an ideal AK treatment has high clinical clearance rates with low 
recurrence with minimal side effects, good cosmetic outcome and low costs. 
4.2 Primary prevention 
Efficient UVR-protection with clothing and broad-spectrum sunscreens, limiting the UVR exposure and 
avoidance of sunbed use are the key points in primary prevention of NMSC and AKs. Sunscreens inhibit the 
formation of UV-induced p53 mutations (Benjamin et al 2007). In immunosuppressed patients, the regular 
use of high sun protection factor (SPF 50+UVA) sunscreen for two years, significantly reduced the number 
of new developing AKs and cSCCs, and also significantly reduced the number of existing AKs (Ulrich C et 
al 2009).  The daily use of sunscreen (SPF 16) in immunocompetent patients for 4.5 years reduced the 
incidence of AKs by 24% (after 2 years but not after 4 years) and cSCCs by 38% (for up to 8 years) 
compared to discretionary use (including no use) (Green et al 1999, Darlington et al 2003, Van der Pols et al 
2006). A sunscreen’s SPF gives us information about the factor by which the sun exposure can be increased 
before skin develops perceptibile erythema (minimal erythema dose, MED). To achieve the adequate SPF 
sunscreens should be applied as a 2 mg/cm2 layer (Petersen et al 20142). Poor compliance and the use of too-
low amounts (0.39 to 1.0 mg/cm2) to achieve the effective SPF of sunscreen reduce the protective effect 
(Neale et al 2002, Petersen et al 20142).  
4.3 Photodynamic therapy 
4.3.1 Mechanism and indications 
Various photosensitizing agents in combination with different wavelengths of light (e.g. psoralens and UVA, 
porphyrins and visible light) are used in photodermatology for the treatment of various skin diseases 
(Hönigsmann 2013).  In photodynamic therapy (PDT), the systemic or topical administration of exogenous 
tumor-localizing photosensitizing drug, followed by irradiation at an adequate wavelength of non-ionizing 
radiation corresponding to the absorbance spectrum of the photosensitizer, leads to phototoxic reaction with 
reactive singlet oxygen causing the death of the target cells (Calzavara-Pinton et al 1996, Ericson et al 
2008).  
40 
 
PDT was invented at the beginning of the 20th century when Oscar Raab observed a toxic reaction caused by 
the combination of visible light, photosensitizer (acridine orange) and oxygen to be lethal to paramecia. In 
1905 von Tappeiner published the first clinical trial in which daylight-PDT with Eosin and Magdala-red 
solution was used in the treatment of facial basal cell carcinomas. In the 1970s and 1990s intravenous 
hematoporphyrin derivate and porfimer sodium causing prolonged photosensitivity, were used. Finally in the 
1990s, the use of topical protoporphyrin IX (PpIX) precursor, 5-aminolevulinic acid, with artificial light, was 
invented by JC Kennedy and colleagues. Soon after this invention photodynamic therapy became a 
widespread treatment for superficial skin cancers and their precursors (Calzavara-Pinton et al 1996, Babilas 
et al 2010, Hönigsmann 2013). 
Currently in dermatology, PDT is widely used in the treatment of AKs and field cancerization, Bowen’s 
disease, superficial (and thin nodular) basal cell carcinomas. It is also used in photorejuvenation, cutaneous 
T-cell lymphoma, acne, warts and some infective (i.e. leishmaniasis, superficial mycoses), and inflammatory 
diseases (morphea, lichen sclerosis, perioral dermatitis, scars) (Ericson et al 2008, Morton et al 20131-2).  
Also some attempts for the treatment of lentigo malignas with PDT exist (Karam et al 2013). Besides 
dermatology, photodynamic therapy with a variety of systemic photosensitizers is widely used in other 
oncologic indications (head and neck cancers, cervix cancer, lung cancer, uveal melanoma) (O’Connor et al 
2009, Soergel et al 2012, Cai et al 2013, Rundle 2014). 
Heme (iron+protoporphyrin IX) is a crucial component in key biomolecules (hemoglobin, myoglobin, 
cytochromes etc.) of living cells (Peng et al 1997).  Normally heme biosynthesis is tightly regulated by a 
feedback mechanism in which free heme inhibits the syhthesis of 5-ALA, to avoid photosensitization. 
Abnormalities in heme synthesis, lead to accumulation of porphyrins and extensive photosensitization 
(porphyria). The first step of the heme biosynthetic pathway is the formation of 5-aminoleavulinic acid (5-
ALA) from glycine and succinyl CoA in mitochondria. The next steps take place in the cytosol where 5-
ALA is converted into porphobilinogen (PBG), and further into uroporphyrinogen and coproporphyrinogen. 
Coproporphyrinogen is then converted into protoporphyrogen IX (PpIX) and combined with iron to form 
heme in the mitochondria (Peng et al 1997), Figure 16. Exogenous 5-ALA becomes a substrate in the heme 
biosynthesis, bypassing the negative feedback control system, and thus leads to intracellular accumulation of 
PpIX in the tissue. It is unclear whether application of 5-ALA ester such as methyl-5-aminolaevulinate 
(MAL), requires an extra metabolic step of ester hydrolysis to convert into 5-ALA which then enters the 
heme pathway, or whether these esters could also act directly as substrates (Fotinos et al 2006). The 
activation of PpIX by visible light leads to the generation of reactive oxygen species (ROS), leading to the 
destruction of cells via apoptosis or necrosis within 10 hours. Fast proliferating malignant tissues have 
increased need for heme, and thus an increased activity of the enzymes (e.g.  porphobilinogen deaminase, 
PBGD) involved in the PpIX development. On the other hand the activity of ferrochelatase enzyme, which 
converts PpIX into heme, is low, which leads to the accumulation of PpIX in malignant tissues (Peng et al 
1997). Additionally, the abnormal stratum corneum in malignant skin is penetrated by photosensitizer more 
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easily than normal skin (Moan et al 2001). It has been suggested that these factors lead in the selective 
uptake of the prodrug and accumulation of PpIX in malignant tissues and further, to their preferred 
sensitization and destruction compared to healthy skin (Babilas et al 2010, Fritsch et al 1998). The main 
target of PDT are mitochondria, but after longer incubation times, PpIX also appears in the cytosol (Peng et 
al 1997). Low concentrations of PpIX in the cell lead to ROS formation only in the mitochondria, leading to 
apoptosis-induced cell death whereas high concentrations lead to ROS generation also in the cytoplasm and 
lysosomes and induce cell necrosis and thus, more severe adverse effects (Castano et al 2006). In addition to 
the direct destruction of the tumor cells, PDT also has an effect on vascularization and the immune system 
usually leading to inflammation that can further destroy residual tumor cells (Castano et al 2006). 
 
Figure 16. Heme biosynthesis from 5-ALA. Figure by Kaisa Timonen, MD, PhD, edited with permission. 
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4.3.2 Photosensitizers 
The first introduced photosensitizer in dermatology was topical Eosin and Magdala-red dye in 1905 
(Hönigsmann 2013). Its use was abandoned due to severe side effects and high tumor recurrence rates. In the 
1970s and 1990s the first generation intravenous photosensitizers: hematoporphyrin derivate (HpD), tin-
protoporphyrin (Sn-Pp) and intravenous porfimer sodium were used for the treatment of NMSC. Due to its 
large molecular size, topical application was impossible and intravenous application led to prolonged 
photosensitization of the whole skin for 6-7 weeks (Calzavara-Pinton et al 1996). In the 1990s also oral 
administration of 5-aminolaevulic acid (5-ALA) for cancer treatment was studied, but the treatment caused 
nausea, vomiting and abnormality in liver function tests (Calzavara-Pinton et al 1996, Webber et al 1997). 
In the 1990s JC Kennedy et al introduced the use of the topical protoporphyrin IX (PpIX) precursor, 5-
aminolevulinic acid (5-ALA) (Hönigsmann 2013). 
Photosensitizers currently available for topical dermatologic use in Europe are low- molecular-weight second 
generation protoporphyrin precursors (Babilas et al 2010) including methyl-5-aminolaevulinate cream  
(MAL 160mg/g corresponding 21% MAL hydrochloride, Metvix®, Galderma, Paris France), a patch 
containing 5-aminolaevulinic acid (5-ALA,  Alacare®, 8 mg solid ALA hydrochloride in a 4 cm2 patch, 
Galderma-Spirig AG, Egerkingen,Switzerland ), and 5-aminolaevulinic acid nanoemulsion gel (BF-200 ALA 
i.e. “Biofrontera ALA”, 78 mg/g corresponding to 10% ALA hydrochloride, Ameluz®, Biofrontera AG 
Leverkusen, Germany). In the USA, a 5-aminolaevulinic acid stick (5-ALA, Levulan®Kerastick, 20% ALA 
hydrochloride, DUSA Pharmaceuticals, Wilmington, MA, USA) is available. In addition, non-standardized 
preparations (e.g. 5-ALA), mixed by hospital pharmacies are commonly used (Wiegell et al 2003).  
Drawbacks associated with the topical use of 5-ALA are its hydrophility causing limited penetration into the 
skin and the instability of the active compound (O’Connor et al 2009, Szeimies et al 20102). It has also been 
suggested that 5-ALA penetrates more easily to the circulation and has a longer lifetime in tissues as 
compared to its esters (Moan et al 2003). Several efforts have been made to overcome these problems 
including physical methods (curettage, micro needling and pretreatment CO2-laser) (Donnelly et al 2008, 
Haedersdal et al 2014), derivatization of 5-ALA into liphophilic esters (Peng et al 1997, O’Connor et al 
2009), and modifying its formulation into a patch or nano-gel (Maisch et al 2010, Szeimies et al 20101, 
Passos et al 2013).  Also chemical skin penetration enhancers, like dimethylsulphoxide (DMSO), have been 
proposed to increase absorption of 5-ALA thus leading to higher PpIX accumulation (De Rosa et al 2000).  
MAL, a lipophilic short chain 5-ALA ester (ALA-CH3), has shown superior selectivity for neoplastic cells 
(Fritsch et al 1998) and greater depth of penetration (O’Connor et al 2009) compared to 5-ALA. Recently, a 
novel oil-in-water 5-ALA nanoforrnulation (BF-200 ALA) gel entered the market, Figure 17.  BF-200 ALA 
has increased stability and improved skin and cell penetration, thus leading to higher and deeper 
accumulation of PpIX in the skin with shorter application times compared to 5-ALA. As a result a low 
concentration (10%) is efficient (Maisch et al 2010, Szeimies et al 20102, Schulten et al 2012). BF-200 ALA 
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and MAL showed similar selectivity for dysplastic tumor cell over healthy keratinocytes and PpIX 
fluorescence was restricted to the application sites in mice implying that neither penetrated to the circulation 
(Schulten et al 2012).  
In addition, also long-chained 5-ALA-esters have been developed.  Hexyl ester (ALA-C6H13),  transport into 
the cells more effectively and thus leads to high PpIX amounts with lower concentrations, and shorter 
application times than needed for 5-ALA,  leading to it being proposed as an alternative photosensitizer in 
topical PDT of skin cancers (Peng et al 1997, De Rosa et al 2003, Morrow et al 2010).  Despite several 
preclinical studies with hexylaminolaevulinate (HAL) (Togsverd-Bo et al 2010, Juzeniene et al 2006, 
Dögnitz et al 2008), it has not yet shown its effectiveness in the treatment of human skin cancers. 
Interestingly, also other novel topical photosensitizers including second generation photosensitizer silicon 
phthalocyanine, and nonporphyrin-based-photosensitizers like the synthetically produced hypericin and 
natural extracts from the plant Hypericum perforatum are under investigation for use in PDT (Skalkos et al 
2006, O´Connor et al 2009). 
Also systemic photosensitizers are used for non-dermatological-PDT. The systemic first generation 
photosensitizer, porfimer sodium, (Photofrin®, Axcan Pharma, Birmingham, AL, USA) is currently used for 
the treatment of lung cancers (Cai et al 2013). There are also second generation systemic photosensitizers 
e.g. temoporfin (Foscan®, Scotia Pharmaceuticals Ltd., UK) ,registered for advanced head and neck cancers, 
and verteporfin (Visudyne®, Novartis, UK), registered for ophthalmologic use (Senge et al 2011, Rundle et 
al 2014). Temoporfin has also been studied for several other indications including brain, gastrointestinal 
cancers, breast cancer and urological malignancies including prostate cancer (Senge et al 2011).  
 
Figure 17. The nanoemulsion (BF-200 ALA) stabilizes 5-ALA and improves penetration through the stratum corneum. 
The inner part of the nanovesicle consists of lipids. 5-ALA binds to the external hydrophilic part of the 
vesicles‘phospholipid monolayer. Figure by Ben Novak, Biofrontera, edited with permission. 
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4.3.3 Light sources 
Light sources used in PDT match the absorption spectrum of PpIX, which has maximum absorption peak at 
410 nm and smaller peaks at 505 nm, 540 nm, 580 nm and 630 nm (Morton et al 20131).  Unlike ionizing 
radiation causing carcinogenesis, PDT can be used several times on the same skin area (Fotinos et al 2006). 
Initially, different coherent laser lights were used in PDT (Moseley 1996).  Nowadays, in conventional PDT, 
both incoherent red visible light (635 nm) and blue light (417nm Blu®-U, DUSA Pharmaceuticals) are used. 
Red light penetrates deeper into the skin, but blue light matches the maximal PpIX absorption peak (410 nm, 
Soret band) and thus may activate PpIX more effectively (Piacquadio et al 2004). Narrow-band light-
emitting diode (LED) lamps (Aktilite®Galderma, Paris, France; Omnilux PDT™ Photo Therapeutics, 
London, UK, and BF-Rhodo LED®, Biofrontera, Leverkusen, Germany; each 630 nm) used with lower 
light-doses (37 J/cm2) and shorter illumination times, which are safer (less heating),  are preferred over the 
broad spectrum lamps which are used with higher light doses (100-170 J/cm2) ( Photodyn® 705/505, 580-
1400 nm , Hydrosun Medizintechnik GmbH, Germany and  Waldman®PDT, 600-750 nm, Waldman-
Medizin-Technik, Germany). Narrow-spectrum light sources have been shown to be more effective 
compared to broad spectrum devices (Pariser et al 2008, Dirschka et al 2012). Also green and white light 
sources, pulsed dye laser, filtered xenon arc, metal halide lamps, and filtered intense pulsed lights (IPLs) 
have been used in PDT (Babilas et al 2010, Morton et al 20131).  Recently, also portable LED-light sources 
(ambulatory-PDT) have emerged (Moseley et al 2006). A limitation of these ambulatory devices is that only 
small areas can be treated simultaneously. 
PDT dosimetry has many variables including the photosensitizer dose, drug-light interval, wavelength, 
irradiance (mW/cm2), and fluence (J/cm2) of light (EDF Guidelines 2014). Total effective fluence takes into 
account the spectral irradiance, tissue transmission, and the absorption of the photosensitizer (Moseley 1996).  
Typically red-LED devices are set to give a standard light dose of 37 J/cm2 in approx.10 minutes  (Moseley 
2005) corresponding to the PplX weighted effective light dose of approx. 1 Jeff ⁄cm
2 (Wiegell et al 20122). 
Daylight is a combination of UVR, visible light and infrared light. The fact that all PpIX absorption peaks 
are within the visual spectrum of light, allows the use of daylight as a light source in PDT (DL-PDT) 
(Wiegell et al 2008, Wiegell et al 20122), Figure 18.  Of the PpIX activation in DL-PDT 87% is caused by 
blue light (380-495 nm), while 10 % is caused by green-yellow (495-590 nm), and 3% by orange-red light 
(590-750 nm). The minimum daylight intensity (illuminance i.e. perceived power of light) during a 2-hour 
exposure should be 100000 lux to match the effective red light dose from traditional LED-PDT, but because 
also other wavelengths activate PpIX, as low as 2300 lux illumination has been suggested to be efficient 
(Wiegell et al 20122). The threshold of 8 Jeff/cm
2 has been set as no association was found between this or 
greater effective light dose and the response rate (Wiegell et al 2009).  In addition to the light dose, also 
outside temperature affects the use of DL-PDT. Meteorological measurements have shown that a >8 J/cm2 
effective light dose in two hours corresponding to an illuminance above 10 000 lux and temperature >10 ̊C 
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are reached in the northern countries (in Iceland, in Finland, 64 ̊ N) until the middle of September and in 
southern counties (Israel 31̊ N) throughout the year, Table 4, (Wiegell et al 2013). However, no correlation 
between efficacy and effective light dose (range 3-46 J/cm2) was found in a recent large multicenter study 
conducted in Australia (Rubel et al 2014). Thus, the accurate effective light dose needed for DL-PDT is still 
unclear. 
Recently, indoor simulated daylight sources (Indoorlux® system, Swiss Red AG, Switzerland) giving an 
illuminance of 15000-25000 lux and irradiance of 21 mW/cm2 at green-yellow (570-590 nm) and 3mW/cm2 
at orange/red (620-640nm) spectral range corresponding to an effective light dose of 14.3-24.2 J/cm2 in two 
hours, have been developed and shown to have successful treatment efficacy for the treatment of AKs 
(Kellner et al 2014).   
 
Figure 18. Daylight spectrum and PpIX spectrum. Edited from Wiegell et al 20122 with permission from John Wiley 
and Sons. 
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Table 4, a) Effective light dose for 2-hour daylight exposure at noon at different latitudes. Effective light doses are 
calculated by weighing the cloud free sky irradiance with the absorption spectrum for PpIX, b) The numbers of days 
with a effective PpIx light dose above 8J/cm2in two hours between 9 a.m and 4 p.m. From Wiegell et al 20122 and 
Wiegell et al 2013, with permission from John Wiley and Sons 
 
4.3.4 Treatment protocols 
In conventional PDT using artificial light sources, the treatment area is prepared with gentle abrasion (e.g. 
tape-stripping) or curettage to remove hyperkeratosis and scales to enhance the penetration of the 
photosensitizers. Then a 1-mm-thick layer of the photosensitizer is applied and covered with light-
impermeable dressing for 3 hours (MAL, BF-200 ALA). Afterwards the photosensitizer is wiped off and 
illumination is performed with an appropriate light matching the PpIX absorption spectrum leading to fast 
activation of high doses of cumulated PpIX (Babilas et al 2010, Dirscka et al 2012). In comparison a 5-ALA 
patch is used without pre-treatment and incubated for 4 hours prior to illumination and a 5-ALA stick is used 
without occlusion and illumination is performed 14-18 hours after the application (EDF Guidelines 2014).  
The disadvantage of the conventional treatment is the impractical delay between the drug application and 
irradiation that burdens the clinics (Moseley et al 2006). 
In DL-PDT, a chemical sunscreen is applied on sun-exposed skin areas, including the treatment area for 15 
minutes before curettage. Afterwards the treatment area is curettaged to remove the crusts and to enhance the 
penetration of the photosensitizer.  The photosensitizer is applied and the area is kept uncovered. After 30 
minutes, the illumination with daylight is performed for 2 hours. This process leads to activation of PpIX 
continuously during its development (Wiegell et al 2011). The use of an organic sunscreen does not affect 
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the efficacy if its absorption spectrum does not overlap the absorption spectrum of PpIX (Wiegell et al 2011, 
Wiegell et al 20122), Figure 19. No difference has been seen in efficacy between 2 and 3 hours daylight 
exposure (Wiegell et al 2011). The use of ablative fractional laser resurfing (AFL) as pretreatment in 
daylight-PDT, may enhance the efficacy of the treatment (Togsverd-Bo et al 2014).   
 
Figure 19. Absorption spectrum PpIX and organic sunscreen (P20®, SPF 20 Riemann & C0. A/S, Hilleroed, 
Denmark). Edited from Wiegell et al 20122 with permission from John Wiley and Sons. 
 
4.3.5 Efficacy 
Conventional PDT 
The placebo-controlled and comparative studies considering different photosensitizers and light sources in 
PDT are listed in Table 5. 
At the 3-month follow-up, MAL-PDT with red LED was superior to vehicle PDT with a lesion complete 
clearance of 86.2% vs. 52.2% and patient complete response of 59.2% vs. 14.9% respectively (Pariser et al 
2008). For 5-ALA-PDT with blue light, lesion complete rate was 91% (25% for vehicle), and the patient 
complete response rate 73% (8% for vehicle) at 3 months (Piacquadio et al 2004).  A sustained lesion 
clearance rate of 78% has been reported for ALA-PDT after one year (Tschen et al 2006). A comparative 
intra-individual (split-scalp) study of MAL vs. 5-ALA LED PDT showed photosensitizers as effective with 
47% vs. 40% patient complete response and 71% vs. 87% lesion complete clearance, respectively (Moloney 
et al 2007). 
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PDT with BF-200 ALA showed higher efficacy compared to placebo-PDT with patient complete response of 
64% vs. 11% and lesion complete clearance of 81% vs. 22% (Szeimies et al 20102). A randomized 
interpatient trial showed patient complete response of 78% vs. 64% vs. 17.1% and a lesion complete 
clearance of 90.4% vs.83.2% vs. 37.1% for BF-200 ALA, MAL and placebo respectively at 3-month follow 
up (Dirschka et al 2012). The sustained patient complete response rates rates at 12 months were 46.7% vs. 
36% for BF-200 AL and MAL, respectively (Dirschka et al 2013). 
Conventional-PDT is more effective for thin (gr I) lesions than for thicker (gr II-III) lesions (Tarstedt et al 
2005). Repeated treatment sessions (two treatments one week apart or a single treatment followed with a 
repetition at 3-months if needed) are thus recommended for thicker lesions treated with conventional 
treatment (Tarstedt et al 2005).  
Daylight-PDT 
Lesion complete clearance rates range from 75.9 to 89.2% for DL-PDT, all conducted with MAL with the 
highest lesion clearance rates seen in a study conducted in Australia (Wiegell et al 2008, 2009, 2011, 20121, 
Rubel et al 2014). In the initial split-face study, PDT using daylight illumination (DL-PDT) showed as 
effective (3-month lesion complete clearance 79% vs. 71%) as conventional PDT for AKs on the face and 
scalp (Wiegell et al 2008). In a large multicenter intraindividual study of DL-PDT for thin AKs conducted in 
Australia, an efficacy of DL PDT was not inferior to conventional-PDT with 3-month lesion complete 
clearance rates of 89.2% vs. 92.8% respectively, of which 96% and 96.6% were still cleared after 6 months 
(Rubel et al 2014). The lesion clearance rates for thicker AKs (61.2% for grade II and 49.1% for grade III) 
treated once with DL-PDT were significantly lower than for thin AKs (75.9%) (Wiegell et al 20121). 
A recent retrospective German study using simulated daylight room and BF-200 ALA showed lesion 
complete clearance rates of 92.8% and patient complete response of 75% after 3 months (Kellner et al 2014) 
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Table 5 Efficacy of LED-PDT and DL-PDT 
4.3.6 Safety  
Both 5-ALA and MAL enter sensory neurons in the free nerve endings in the epidermis via GAT-3 
transporter and thus can generate severe pain during their activation (Novak et al 2011). This is due to 
accumulation and sudden activation of high amounts of PpIX during occlusion.  To reduce the pain, local 
anesthesia, cold air analgesia or nerve blocks can be used. The use of topical analgesia is not recommended 
for two reasons: their high pH might chemically inactivate the photosensitizer, and they might induce local 
vasoconstriction reducing the oxygen-dependent event. Other common adverse effects of PDT include 
erythema and edema with erosion, crusting and scaling healing over 2-6 weeks. Localized photosensitivity 
can be present for up to 48 hours post treatment while PpIX is still formed (Petersen et al 20141). The half-
life is approx. 24 h for 5-ALA and 48 h for MAL (Morton et al 20131). Pruritus, and rarely ulceration, 
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blistering, scarring, hair loss or post-inflammatory hyper-/hypopigmentation may occur (Morton et al 20131, 
Babilas et al 2010).  Allergic contact dermatitis to photosensitizing agent has been reported for both 5-ALA 
and MAL. It seems more likely that sensitization develops to methylester, and 5-ALA may cross-react 
(Gniazdowska et al 1998, Wulf et al 2004).  Risks as high as 35% for sensitization after several MAL-PDT 
sessions have been reported and the question has been put forward whether the persistent inflammatory 
reactions could actually be caused by contact dermatitis (Korshøj et al 2009). Allergic contact dermatitis can 
occur also from occupational exposure to MAL (Antonia Pastor-Nieto et al 2011). In addition, PDT can 
induce re-activation of herpes simplex (Ribeiro et al 2012). There are a few reports of melanomas on post-
treatment PDT areas, but they have been considered as incidental events (Babilas et al 2010). 
The adverse effect profiles in MAL and 5-ALA PDT are similar (Pariser et al 2008, Piacquadio et al 2004), 
but MAL-PDT is less painful than 5-ALA-PDT (Moloney et al 2007, Wiegell et al 2003). This might be due 
to lower PpIX production by MAL (Novak et al 2011). BF-200 ALA-PDT showed similar pain values, and 
skin reactions with MAL (Dirschka 2012). Adverse reactions can be reduced by lowering photosensitizer 
concentration and thus the PpIX dose (Fabricius et al 2013). However, 8% and 16 % MAL concentrations 
provided similar adverse reactions to DL-PDT (Wiegell et al 2009). Adverse reaction can also be reduced by 
post-treatment use of topical corticosteroids (Wiegell et al 2014), a cream containing metal ions (e.g. ferrous 
sulfate) (Juzenas et al 2010), or physical sunscreen (Petersen et al 20141). 
Due to continuous activation of PpIX during its development, DL-PDT is less painful with mean pain scores 
of  0.8±1.2 (range 0 to 5) vs. 5.7±2.3 (range 0 to10 ) and maximal pain scores of 2.0 (SD±1.9) 6.7(SD±2.2) 
(numerical scale 0-10) compared to LED-PDT (Wiegell et al 2008, Rubel et al 2014). However, in cases of 
delay from application of the photosensitizer to daylight exposure or a long pause during exposure, PpIX is 
accumulated and the treatment might be more painful. Also longer than 3-hour exposure times are associated 
with higher pain values (Wiegell et al 2011). The use of sunscreen during DL-PDT reduces adverse effects. 
In the initial DL-PDT vs.conventional split-face study, where no sunscreen was used, 42% of the patients 
had more severe erythema and crusting on the DL-PDT sites compared to 21% on the LED-PDT sites 
(Wiegell et al 2008). When sunscreen was used, fewer adverse reaction were seen in the DL-PDT group 
(39%) compared to the LED-PDT group (59%) (Rubel et al 2014).  
In conclusion PDT has several advantages over other AK therapies. It can be performed as an office- or 
hospital based treatment during one day, has shorter adverse reaction periods compared to most of the home-
based topically applied field-therapies (Braathen et al 2012). Large areas can be treated during a single 
session with high clearance rates. In addition, PDT provides an excellent cosmetic outcome (Rubel et al 
2014). Coampared to LED-PDT, DL-PDT provides further advantages as it is nearly painless and more 
convenient due to shorter clinic visits (Wiegell et al 20122). 
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4.5 Other therapies 
In Europe, over 90% of AKs are treated non-surgically, with liquid nitrogen (LN) cryotherapy being the 
most frequently used treatment (>60% of the nonsurgical treatments). Newer field-directed treatments, 
directed for the treatment of multiple lesions, are still waiting to exceed the ablative treatments (i.e. LN 
cryotherapy) (Ferrandiz et al 2012). 
4.5.1 Ablative therapies  
Ablative therapies physically destroy the target lesion, without any effect on surrounding field-cancerized 
area and thus leading to “new cancers” (Ulrich 2009), they are recommended only for single and thin lesions 
(Ceilley et al 2013). Ablative therapies include surgical procedures (most commonly curettage with 
electrosurgery) and LN cryotherapy.   
LN cryotherapy, being quick and low-cost, is the most commonly used ablative therapy. It is based on quick 
freezing causing intracellular destruction of the target tissue. Keratinocytes are destroyed at temperatures of -
20 - -30̊C (Suhonen et al 2005).  The overall lesion complete clearance rates were 67.2% after 3 months for 
gr I-II AKs, while patient complete response was 57% with excellent cosmetic outcome in approx. 50% of 
the lesions. The freeze duration influenced the clearance rate with a complete lesion clearance rate of 39%, 
69% and 83% with freezing times of less than 5s, greater than 5s, and greater than 20s, respectively (Thai et 
al 2004). However, a more aggressive approach may result in hypopigmentation (due to the destruction of 
melanocytes) and scarring. Other adverse effects include pain, redness, crusting, hair loss at the treatment 
site, and the potential for infection (Stockfleth 2012). LN cryotherapy can be used in combination with field-
directed therapies (Samrao et al 2013).  
Curettage with electrodessication can be used for large/hypertrophic lesions, although histologic verification 
to rule out cSCC is more recommendable. More commonly curettage is used to debride hyperkeratotic AKs 
before LN cryotherapy. Shave biopsies followed by electrocautery can also be used (Ceilley et al 2013). 
Some ablative therapies (dermabrasion, chemical peels and carbon dioxide laser) are sometimes used to 
treat larger photodamaged fields, but are mainly focused on skin rejuvenation (Ceilley et al 2013). 
 
4.5.2 Field-directed chemotherapies 
Topical field-directed therapies cause a localized inflammatory skin reaction leading to the elimination of 
AKs. These therapies are recommended for areas of multiple AKs. The long treatment times (except for 
ingenol mebutate) with prolonged local skin reactions, cost of the treatment and cognitive problems (i.e. an 
inability to understand the treatment plan or to properly use medication) may cause nonadherence (Ceilley et 
al 2013). Evidence for the efficiency of various treatments for AKs vary from the systematic review of 
randomized trials for 5-fluorouracil and imiquimod, to randomized trials for diclofenac and ingenol 
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mebutate, to case series for newer topical agents (i.e. resiquimod, piroxicam, betulinic acid and potassium 
dobesilate) (Micali et al 2014). 
5-Fluorouracil (5-FU), a fluoropyrimidine antimetabolite that stops the growth of rapidly proliferating 
(cancerous) cells by disturbing DNA and RNA synthesis, has been used since the 1960s for dermatological 
(pre)cancerous conditions (Stockfleth 2012). 5-FU widely available as a topical cream or solution (Efudex® 
5% or 2% FU, Fluoroplex® 1% 5-FU, Carac ® 0.5% 5-FU, Actikerall® 0.5% 5-FU+10% salicylic acid). In 
Finland 5-FU is approved but not currently marketed. The highest response rates have been reported for daily 
use of the 5% cream for 2-4 weeks. Also prolonged applications 1-2 times a week for 6-7 weeks have been 
used. A systematic review evaluated patient complete response rates (overall 80% reduction in lesion count) 
at 2-12 months to be 49% for the 5% formulation and 34.8% for the 0.5% formulation (Micali et al 2014). 
Lesion clearance rates vary from up to 96% in controlled clinical trials to 50-70% at one year in clinical 
practice, which has been explained by nonadherence and common side effects (erythema, erosion, 
desquamation, burning sensation, pruritus, more rarely secondary infections, scarring and discoloration) 
(Samrao et al 2013).  
Imiquimod is a toll-like receptor-7 agonist that modifies the immune response and stimulates apoptosis thus 
disturbing tumor proliferation (Stockfleth 2012). Imiquimod is available in Europe in the following 
concentrations: 5% (Aldara®) and as 3.75% and 2.5% (Zyclara® 2.5% and 3.75%) cream formulations 
(Samrao et al 2013). The duration of the treatment varies from two 2-week cycles of daily application 
(3.75% and 2.5% cream solutions) to up to 16 week (3 times per week use, 5% cream) resulting in up to 85% 
lesion complete clearance at one month, 45-48% histologic lesion clearance and 31-84% patient complete 
response two months after treatment (Samrao et al 2013, Micali et al 2014). In a long term follow-up of two 
years, 20 % of the patients treated with imiquimod had developed new AKs compared with 90% in a placebo 
group (Stockfleth et al 2004). The side effects include erythema, burning, pain, erosion and ulceration. 
However, imiquimod is better tolerated than 5-FU (Samrao et al 2013). 
Diclofenac is a nonsteroidal anti-inflammatory drug used in combination with hyaluronic acid which 
supports transport into the epidermis (Solaraze®;3% diclofenac+2.5% hyaluronic acid). Diclofenac acts 
through anti-inflammation by inhibiting cyclooxygenase (COX-2) production, and it also has anti-
angiogenetic and apoptose-inducing effects (Maltusch et al 2011). The duration of treatment with this drug is 
long, being 60-90 days .The side effects (mild erythema, pruritus) are milder than with FU or imiquimod 
(Samrao et al 2013). Patient complete response rates of 33-50% have been reported after 60-90 days 
treatment and thus its efficacy appears to be lower than that of other topical treatments (Micali et al 2014). 
Ingenol mebutate, a macrocyclic diterpene ester extracted from the plant Euphorbia peplus, induces a rapid 
necrosis of primary tumors and stimulates a neutrophil-mediated immune response cytotoxic to residual 
tumor cells (Stockfleth 2012). Treatment with ingenol mebutate significantly reduces mutant p53 
keratinocyte patches (Cozzi et al 2012).   This relative new treatment is available in 0.05% and 0.015% gels 
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(Picato®). The milder formulation is applied once a day for three days to AK on the face or scalp, and 
stronger formulation once a day for two days on the body. Lesion complete clearance rates of 87% at two 
months, sustained at one year, and patient response rates of 37-47% at two months of which 44-46% were 
sustained at one year have been reported (Lebwohl et al 2013). Adverse effects include erythema, scaling and 
scabbing. The advantage is its short application time enhancing patient adherence but a limitation is that the 
treatment should be limited to 25 cm2 areas (Micali et al 2014). 
New topical agents including 5-FU combined with salicylic acid, resiquimod, piroxicam, betulinic acid and 
potassium dobesilate are under investigation for the treatment of AKs (Samrao et al 2013, Micali et al 2014). 
Topical difluoromethylornithine (DFMO) inhibits the enzyme ornithine decarboxylase (ODC), which when 
induced by UV-radiation initiates tumor growth.DFMO is currently studied for chemoprevention and 
treatment of AKs (Pommergaard et al 2013). 
4.5.3 Efficacy of PDT compared with other therapies 
Most of the AK treatment trials are placebo-controlled but comparative studies of different treatments are 
rare and thus information on treatments relative efficacy is limited. In addition, due to the continuum of sun-
damaged skin and AKs, counting AKs appear to be unreliable and variation exists even among experienced 
dermatologists, which interferes with the accuracy of the results (Weinstock et al 2001). Varying end points 
(lesion vs. patient clearance rates (75%, 100%), preventive effect i.e. counting new lesions) and follow up 
periods (1-24 months) complicates comparisons between studies.  AK counts can also change spontaneously 
with high regression and recurrence rates (Werner et al 2013).  
A multicenter study comparing LN cryotherapy and conventional MAL-PDT (1-2 sessions 12 week apart) 
showed significantly higher lesion complete clearance rates for LN cryotherapy (88%) than for MAL-PDT 
(78%) (Kaufmann et al 2008). In a randomized intra-individual split-face study, MAL-PDT (one treatment 
session, repeated at 3 months if needed) and LN cryotherapy (double freeze-thaw, repeated if needed at 3 
months) showed higher clearance rates for PDT (86.9% vs. 76.2%) at 3 months before retreatments and 
equal clearance rates: 89.1% vs. 86.1% respectively for MAL-PDT and LN cryotherapy at 6 months. Fewer 
side effects were reported with MAL-PDT than with LN cryotherapy (Morton et al 2006). MAL-PDT as a 
single session was proven to be as effective (69% vs. 75% clearance), and two treatment sessions of MAL-
PDT more effective (91% vs. 68% clearance) than LN cryotherapy (Babilas et al 2010). All the studies 
reported significantly better cosmetic outcome and patient-preference for PDT  ´than for LN cryotherapy. 
A network meta-analysis based on Cochrane review ranked FU at 0.5-5% concentrations to be the most 
effective treatment followed by  ALA-PDT (all photosensitizers, narrow and broad spectrum red and blue 
lamps) ≈ imiquimod ≈ ingenol mebutatate  ≈MAL-PDT> LN cryotherapy> diclofenac+hyaluronic acid> 
placebo (Gupta et al 2013). The analysis ranked the complete patient clearance and did not value tolerability, 
costs or cosmetic outcome. 
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Another recent network meta-analysis based on the same Cochrane review  valued the effect of different 
ALA-agents and different concentrations of imiquimod,  and showed  the highest probability for complete 
patient clearance (75.8%) for LED-PDT with BF-200 ALA, followed by imiquimod  (63.3% for 5% cream 
16-week-treatment , 56.3% for 5% cream 4-week-treatment, 39.9% for 3.75% cream  4-week treatment ),  5-
FU 0.5% (59.9%), ALA-patch LED-PDT (56.8%), MAL LED-PDT (54.8%), ingenol mebutate (54.5%),  LN 
cryotherapy (38.2%), diclofenac 3%+hyaluronic acid (24.7%) and placebo (6.9%) . However, this study 
excluded 5% FU cream and was funded by Biofrontera (Vegter et al 2014). 
4.5.4 Secondary prevention 
Despite several treatment options for AKs, only a few of them have been shown to be effective for secondary 
prevention of new AKs and cSCCs. Photodynamic therapy (PDT) is widely studied for secondary prevention 
of AKs and cSCCs (Bissonnette 2007). In UV-radiated mice, topical MAL-PDT significantly delayed and 
reduced the number of developed AKs and cSCCs (Sharfaei et al 2002). A single treatment with 
conventional PDT has been shown to delay the development of new lesions (mostly AKs, also warts and 
keratoacantomas, no cSCC developed) in renal transplant recipients (Wulf et al 2006). In immunocompetent 
patients, with previous NMSC, conventional 5-ALA-PDT significantly reduced the number of newly 
developed AKs compared to placebo-PDT (Apalla et al 2010). In organ transplant patients, repeated 
conventional MAL-PDT reduced the number of new AKs (Wennberg et al 2008) .When ALA-PDT was used 
without curettage as a single session no preventive effect was seen in the development of cSCCs although a 
trend for decreased “keratotic lesions” was seen in OTR patients (de Graaf et al 2006). MAL-PDT and 
imiquimod 5% effectively prevented the appearance of the new AKs, however, the study was not placebo-
controlled (Sotiriou et al 2014).  In a recent placebo-controlled trial topical retinoid (0.1% tretinoin) was 
shown to be ineffective in the prevention of AKs and NMSC (Weinstock et al 2012). Topical diclofenac 
(NSAID), calcipotriol (vitamin D-3 analog), and difluoromethylornithine (DFMO) as monotherapy failed to 
prevent NMSC but a combination of diclonefac+DFMO and diclonefac+calsipotriol reduced tumor 
incidence and size of the tumors compared to placebo  in UV-radiated  mice (Pommergaard et al 2013). 
Currently no evidence exists for a chemopreventive effect of topical FU or ingenol mebutate.   
4.6 Principles of the cost-effectiveness analysis 
Taking into account the high AK prevalence rates, AK treatments cause also a significant economical burden 
to society. As a high percentage of patients with field cancerized skin require repeated treatments (Ceilley et 
al 2013), an ideal AK treatment should not only be effective and well tolerated, but also provide 
economically good value for money i.e. have a good balance between the costs and benefits. Here I will 
briefly review the terminology regarding the economic evaluation, which could be used to assist decision 
making between different treatment options. 
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Efficacy means the outcome of a treatment in an ideal situation like in a controlled trial (i.e. does the 
treatment work?). Effectiveness means the outcome of a treatment in everyday practice (i.e. does the 
treatment work in real life?). Efficiency is the net ratio between a treatment’s effectiveness and the required 
resources (i.e. is it worth it?). Cost-utility analysis takes into account the effectiveness of the intervention, 
and patients’ morbidity and mortality. Cost-utility can be expressed in terms of cost per a quality adjusted 
life year (QALY) gained (Robinson R 19931). Cost-minimization analysis can be used to identify the least 
costly treatment option if it can be assumed that two options provide similar treatment outcomes (Robinson R 
19931). Cost-effectiveness analysis (CEA) includes a systematic comparison of the relative health care costs 
and benefits and thus provides information on whether the intervention provides good value for money (i.e. 
what is the most effective way to use the resources?) (Gordon et al 2014). This approach can be used when 
the outcomes of the interventions may vary between the interventions (Robinson R 19931). The results of 
CEA are expressed in terms of cost per unit of outcome (Robinson R 19931). The incremental cost-
effectiveness ratio (ICER) is the ratio between the net costs and the net effects of two interventions (A and 
B). ICER can be calculated using the formula: 
 
ICER= (cost of intervention B – A) - (savings of intervention B-A)/effects of intervention B-A 
 
If this ratio is low, the intervention B is said to be cost-effective (Caekelbergh et al 2006). To reduce 
uncertainty of the results of the CEA, the results can be tested with a sensitivity analysis (Robinson R 19932). 
There are different types of sensitivity analyses including a simple sensitivity analysis, an extreme scenario 
analysis and a probabilistic sensitivity analysis; all of these investigate the extent to which results are 
sensitive to alternative assumptions. An ideal economic evaluation should be conducted along prospective 
clinical trials, which rarely is the case (Robinson R 19932). Most of the cost-effectiveness studies of AK 
treatments are funded by drug companies and use estimated and modeled values instead of prospective study 
designs. In addition, they commonly fail to use proper sensitivity analyses. The studies considering cost-
effectiveness of different AK treatments are detailed in the Discussion section. 
 
5. TREATMENT OF LENTIGO MALIGNA (MELANOMA) 
5.1 Prevention 
LMs are treated in order to prevent the development of invasive LMMs. Sunscreens can be used in the 
prevention of melanomas (Hirst et al 2012). To our knowledge, no specific studies that consider the 
prevention of LMs exist. 
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5.2 Surgical treatment of LM 
The standard treatment for LM and invasive LMM is wide surgical excision. The current recommendations 
for clinical excision margins are the following: 0.5-1 cm for in situ melanoma (LM), 1 cm for melanomas 
equal or under 1 mm in Breslow thickness, 1-2 cm for melanomas 1,01-2.0 mm in Breslow thickness and 2 
cm for melanomas over 2.0 mm in Breslow thickness (Bichakjian et al 2011). Lentigo maligna subtype 
melanomas often represent wide (several mm to several cm) superficial subclinical extension and thus wider 
margins are suggested for their adequate removal (Bichakjian et al 2011). Another challenge in LM excision 
is their frequent location on the facial area where wide excision can cause serious morbidity and thus 
surgeons may attempt to limit any deformity by using less safety margins than recommended (Debloom et al 
2010). 
LM/LMMs are typically located on sun-damaged dispigmented skin areas; this complicates the assessment 
of the lesion borders and thus achievement of adequate margins. After standard surgical wide excision of LM 
with 5 mm margins, recurrence rates vary between 6-20% (Erickson et al 2010). The width of the required 
surgical margin is significantly related to the lesion thickness (Bricca et al 2005). The average margins 
required to clear LM and LMM were 7.1 mm and 10.3 mm, respectively (Hazan et al 2008). Sixty percent of 
patients with the majority of in situ lesions required a 10-mm margin and two or more stages of excisions 
(Bosbous et al 2009).  Nine-mm margins have shown their superiority over 6-mm margins with adequate 
removal of 99% of LMs (Kunishige et al 2012). In addition, larger LMs require wider margins than do 
smaller lesions due to their greater subclinical components (Bub et al 2004, Hazan et al 2008). Up to the 
present the question: “How wide is wide enough?” remains controversial. 
Considering the high recurrence rates, it has been argued that residual LMs are unlikely to be detected in 
routine cross-sectioning “bread-loafing” histology which enables the detection of 1% of the true specimen 
margins (Osborne et al 2002, Bosbous et al 2010).  The accuracy of cross-sectioning for finding positive 
margins is directly dependent on the interval between the cross-sectional cuts with a sensitivity of 50% for 
cross-sectioning performed every 1 mm and as low as 7% when sectioning is performed every 4 mms 
(Kimyai-Asadi et al 2007). Consequently, cross-sectioning must be performed every 0.1 mm to meet the 
100% specimen margin requirement.  Mohs micrographic surgery (MMS), using horizontal sectioning of 
frozen excised tissue, has been developed to solve this problem. MMS potentially allows the excision of the 
smallest amount of tissue by confirming histologic clearance of 100% of the peripheral margins (Clark et al 
2008). Nevertheless, in frozen sections malignant melanocytes are poorly visualized due to processing 
artifacts, melanocyte-mimicking vacuolated keratinocytes mimicking, and obscuring dermal inflammatory 
cells, and thus MMS is not a very suitable technique for LM or LMM excisions.  Variations of the MMS 
technique, called staged surgical excisions (SSE), using permanent formalin-fixed sectioning and/or 
immunostainings (e.g. Mel-A/MART-1, Mel-5, S-100, HMB-45), are used for more accurate detection of the 
melanocytes. Traditional Mohs surgery reports from nil to up to 33% and its variants 0-9.7% recurrence rates 
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for LM, respectively (Erickson et al 2010, McLeod et al 2011). The center of the tumor should always be 
sent for permanent vertical sectioning in order to rule out an invasive component (Iorizzo et al 2013).  
5.3 Non-surgical treatment of LM 
There are also non-invasive treatment options for LM but their efficacy has not been established and they 
should only be considered when surgical excision is not realistic. Non-surgical treatments options include 
topical imiquimod, radiation therapy, LN cryotherapy (Bichakjian et al 2011). In addition lasers, PDT and 
tazarotene gel have been studied for this use (Cotter et al 2008, Bosbous et al 2010, Karam et al 2013).  A 
disadvantage of non-invasive treatments is the lack of the histological examination of the whole lesion for 
hidden invasive components (Erickson et al 2010). In addition, clinical follow-up of LMs may be 
challenging due to treatment-induced pigmentation (Cotter et al 2008) and amelanotic recurrences (Fleming 
et al 2004). 
Imiquimod shows 66-100% clinical and 53-75% histologically confirmed clearance rates for LM (Micali et 
al 2014). The effect is claimed to be caused by activation of the immune response, especially interferon-α 
which also has effect in systemic treatment of metastatic melanoma (Erickson et al 2010).  However, 
reported follow-up periods are limited (12-18 months) and in most studies histologic verification was only 
available from partial biopsies and thus there are inadequate data to prove the efficacy.  Progression to 
invasive melanoma may occur under treatment with imiquimod (Cotter et al 2008). The level of evidence of 
topical pharmacotherapy for LM treatment is IV (case series) (Micali et al 2014). Imiquimod treatment may 
remove the visible pigment while no clearance is seen histologically (Fleming et al 2004) and also produce 
post-treatment pigmentation which may be misdiagnosed as a recurrence (Cotter et al 2008). 
Radiation therapy has been reported to be effective in LM treatment with clinical cure rates of 86-95%. 
However, histological clearance reports are not available and the studies include relatively low numbers of 
patients with short (2-5 years) follow-up periods (Erickson et al 2010, Bichakjian et al 2011).The high 
voltage schedules (100-280 kV up to 5-6 mm depth) are effective but induce a risk for adverse effects while 
low voltage (10-50kV) reach only up to 1mm which may be insufficient to destroy the malignant 
melanocytes deeper down the follicular structures (Bosbous et al 2010).Thus, radiation therapy should be 
considered as a second-line treatment option only if surgery is contra-indicated. In addition, also ultra-soft x-
ray i.e. grenz-ray (GR) treatment is used for the treatment of LM (Hedblad MA et al 2012). 
Melanocytes are more sensitive to cold injury than keratinocytes. Cryotherapy for LM shows varying clinical 
clearance rates (65.7-93.4). Studies done with this technique to date fail to report the histological clearance 
and long-term follow-up, and are not controlled and thus cryotherapy is not recommended for LM (Bosbous 
et al 2010, Bichakjian et al 2011).  
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Several lasers (argon, carbon dioxide, Q-switched Nd: YAG, Q-switched ruby) have been studied for the 
treatment of LM. However, the recurrence rates are high (40-50%) and thus laser treatment is not 
recommendable for LM (Bosbous et al 2010). 
One study experimentally used PDT (light doses 40-90 J/cm2 and 3-9 sessions) for treatment of LM. It has 
been suggested that the effect is probably due to PpIX binding to benzodiazepine receptors and thus affecting 
the proliferation of and differentiation of melanoma cells. Complete clinical and histological clearance was 
found in 12 of 15 (80%) cases (Karam et al 2013).However, the follow-up period was short (10-29 months) 
and histology was only performed from partial treatment areas and thus the results are rather unreliable. 
In addition retinoids (tazaroten gel 0.1%) have been suggested to enhance the effect of topical imiquimod 
(Cotter et al 2008). 
 
AIMS OF THE PRESENT STUDY 
1. To study the feasibility of a novel hypespectral imaging system (HIS) in preoperative lesion margin 
assessment of subclinical borders of LM and LMM 
2. To study HIS in the detection of inpicient subclinical AKs and field cancerization 
3. To study the effectiveness and safety of a novel photosensitizer formulation, 5-ALA nanoemulsion (BF-
200 ALA), in DL-PDT for AKs and field cancerization 
4. To study the effect of repeated treatment sessions for grade II-III AKs in DL-PDT 
5. To study the histological and immunohistochemical effects of DL- PDT 
6. To assess the cost-effectiveness of DL-PDT compared to LED-PDT in the treatment of AKs 
 
METHODS 
1. PATIENTS  
The study was performed in accordance with the Declaration of Helsinki, and the study protocols were 
approved by the Ethics Committee of Tampere university District. Patients were recruited from the 
Department of Dermatology in Päijät-Häme central hospital.  All patients gave their written informed 
consent for their participation. 
Study I was conducted between 2012 and 2014, study II between 2011 and 2012, study III in 2013, and 
study IV between 2011 and 2014. The patient characteristics are shown in Table 6. Altogether 121 patients 
were included in the studies.  
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In study I we included patients with suspected LM or LMM on their faces or scalps. In addition to 19 
patients described in article I, four additional patients who were recruited after submitting the paper will be 
presented. Study II was implemented in two phases. The inclusion criteria for phase one was at least three 
clinical AKs located on the same area on the face or scalp. For phase two we included less photodamaged 
patients with at least one AK on their faces, scalps or necks. Inclusion criteria in study III was at least two 
symmetrically located clinically similarly graded AKs ≥6 mm in diameter on face or scalp. For study IV we 
included patients with at least three clearly detectable AKs on the face or scalp. In studies II-IV AKs were 
clinically graded into three grades according to Olsen et al: I, mild (slightly palpable AK, more easily felt 
than seen); II, moderate (moderately thick AK, easily seen and felt); III, thick (very thick or obvious AK) 
(Olsen et al 1991). All AK grades were included. Exclusion criteria for all studies were lactation, pregnancy 
and likelihood of non-compliance. In addition exclusion criteria for studies II-IV were immunosuppression, 
known history of porphyria or photosensitivity, allergic reaction to ingredients of the photosensitizers or 
treatment of the studied skin areas 3 months earlier. 
 
 
Table 6. Patient characteristics studies I-IV * one patient participated in studies II and IV 
 
2. PHOTOGRAPHING AND FLUORESCENCE IMAGING 
All studied lesions were photographed (Canon Ixus 130 or Olympus Pen Lite E-pl5). Fluorescence detection 
with Wood’s light was used in studies I and II.  
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In study I we used Wood’s light (320-400 nm, peak 365 nm, Philips Burton®, Somerset, USA) to help in 
defining the borders of LM and LMM preoperatively.  In this UV light lesion were photographed and their 
borders were marked with a black pen, photographed, and compared with those assessed with a hyperspectral 
camera.  
In study II and phase one we used PpIX fluorescence detection to find the subclinical AKs. After marking 
and photographing the clinical lesions a standard 1 mm-layer of MAL, evaluated by the researcher,  was 
applied on 12–70 cm2 areas surrounding them and kept occluded for three to four hours under a light-
impermeable cover (Tegaderm matrix wrap and aluminum foil). Afterwards the MAL was wiped off with 
sodium chloride liquid and the area was illuminated with Wood’s light (Philips Burton®, Somerset, USA). 
The fluorescence was documented with a digital camera (Canon Ixus 130) and the most brightly fluorescent 
areas were marked with a blue pen and photographed again. All the marked areas were kept covered by a 
cloth and aluminum foil for 2–3 days to avoid activation of the MAL-induced pIX. Two to three days later 
when the MAL had vanished, we took the hyperspectral images and punch biopsies. In phase two of the 
same study we took hyperspectral images of the naive AKs followed by a biopsy, Figure 20.  
 
Figure 20. Flow chart for study II 
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3. HYPERSPECTRAL IMAGING 
Hyperspectral imaging was used in study I to assess the subclinical borders of LM and in study II to detect 
the areas of incipient subclinical AKs.  
3.1 Device 
The handheld hyperspectral imaging system (HIS) was developed for the study at the VTT Technical 
Research Centre of Finland and the data processing was developed by the University of Jyväskylä, Finland, 
Figure 21. The technical characteristics are detailed in the appendix of the original article I and in Pölönen 
et al 2013. The prototype imaging system consisted of a novel small sized hyperspectral imager (VTT FPI 
VIS-VNIR Spectral Camera, 500-850 nm) (Saari et al 2010 and 2013), an external light source of visible 
and infrared light (500-850 nm), a fiber optic ring light, and a holder for the imager and the ring light.The 
used hyperspectral imager is based on a Fabry-Perot interferometer (FPI) which enables the use of tuneable 
wavebands and thus detection of the whole waveband range rapidly compared to scanning prism techniques. 
The imager’s spectral bands widths are 5–10 nm. We used 70 wavebands between 500 and 850 nm. FPI 
allows changes to be made to the wavelengths in milliseconds. The imaged data was transferred from the 
camera to a laptop via a USB cable. Images with 320x240 pixel spatial resolutions were taken with a five-
megapixel image sensor using 8x8 binning. Binning enables one pixel on the image to contain information 
from 8x8 pixels on the image sensor, which improves the signal-to-noise ratio and makes the sensor more 
sensitive to light. With the 12 cm2 field of view (FOV) the spatial resolution was 6400 pixels/cm2. The size 
of one pixel was approx. 125μm. The imaging depth was approx. 2 mm. The weight of the handheld system 
was approx. 1.2 kg. 
In study I all 23 lesions were imaged at their naive state prior to any surgical procedure. In study II phase 
one, hyperspectral images were taken 2-3 days after the fluorescence imaging process when we assumed 
there was no MAL fluorescence left. In phase two of study II no fluorescence imaging was used and the 
images were taken directly before the biopsies. HIS acquired the diffuse reflectance of the detected skin 
areas rapidly in a few seconds.  
 
Figure 21. The handheld hyperspectral imager (VTT FPI VIS-VNIR Spectral Camera). 
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3.2 Hyperspectral data analysis 
There are different approaches to analyze hyperspectral data including supervised classification algorithms 
and unsupervised linear spectral unmixing (Harris 2006). In our study, two different methods were used in 
analyzing the data from the acquired hyperspectral data cube, Figure 22. In study I the data was analyzed 
using the linear signal unmixing method. In study II we used both supervised neural network analysis, and 
unsupervised linear signal unmixing analysis.  
In the unsupervised linear signal unmixing we assumed that the obtained spectra were a linear mixture of the 
pure spectra.  In this method the acquired hyperspectral data was analyzed using the assumption that it 
complied with the linear mixture model (vertex component analysis, VCA and filter vector algorithm FVA) 
(Nascimento et al 2005, Bowles et al 1995, Bro et al 1997) to achieve pure spectra (endmembers) of the 
lesional and healthy skin and to produce abundance maps of  their diffuse reflectance.These abundance maps 
each represented different pure pixels and their appearance in the image and were used for detection of field 
cancerized skin areas and for delineation of the LM borders. The analysis methods are detailed in another 
thesis (Pölönen et al 2013). 
The supervised method was a classical feed forward neural network method with multi-layer perceptron 
(Ripley 1996). This method had to be trained with “healthy” and “sick” data sets. We used training areas 
from 1) clinical AKs, 2) subclinical AKs detected earlier by their PpIX fluorescence, and 3) from healthy-
looking non-fluorescent skin. The neural network method provided map-like diffuse reflectance images with 
binary results (“sick/not sick”) of the whole obtained area. 
 
 
Figure 22. Hyperspectral data analysis process. Figure by Ilkka Pölönen, PhD, with permission. 
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4. HISTOPATHOLOGICAL AND IMMUNOHISTOCHEMICAL METHODS 
4.1 Sampling techniques 
In study I six of the 23 LM/LMM lesions were biopsied before recruiting to the study and immediately 
excised with wide margins after the imaging processes.  To help map the findings for 17/23 patients, we took 
targeted 3 mm punch biopsies (1-3 per patient) from the middle and from the lesions’ borders, defined using 
the HIS, and afterwards the lesions were completely excised with wide excision margins. In addition to 
better evaluate the subclinical extension of the lesion borders 10 of 23 lesions were excised directly at the 
clinical border shown by Wood’s light and the 5-mm margin border was excised as a separate 5 mm 
circumferential strip. The biopsy sites and excision margins were marked and photographed. The edges of 
the specimens were marked with orienting sutures, inked and oriented on a map.  In the four additional 
patients all lesions were excised using a separate circumferential strip. 
In study II phase one, we took 4-5 punch biopsies (3 mm diameter) per patient after all the imaging 
procedures.  The sampling sites were (1) clinical AK, (2) subclinical AK detected by its strong fluorescence 
and/or HIS, (3) healthy looking skin showing no or weak fluorescence. For ethical reasons, we could not 
biopsy all the clinical and subclinical AK on the wide cosmetically sensitive areas, and thus the sampling 
sites had to be limited. In phase two of the same study we limited the biopsies to one per patient to verify the 
diagnosis of the clinical AKs. 
In study III we took 3-mm-punch biopsies from symmetrically located equally graded AKs ≥ 6 mm in 
diameter prior to treatment and again at the 3-month follow-up visit. The control biopsies were taken from 
the same lesion, but avoiding the previous biopsy site to eliminate the changes from scar formation. No 
biopsies were taken in study IV. 
All the biopsy samples were fixed (10% formalin), embedded in paraffin, sectioned (3 μm thickness), and 
stained with hematoxylin and eosin (HE) using standard methods. We used vertical permanent sectioning for 
all the lesions. 
4.2 Histopathology and immunohistochemistry 
A specialist in dermatopathology (Leila Jeskanen) interpreted all the samples for the LM study 
(I).Immunohistochemical stainings for MART-1/Melan A was used in 7/23 cases and S-100 staining in one 
case.  
In studies II-III a specialist in pathology (Taneli Tani) interpreted the specimens in a randomized order, 
being unaware of the site and the identification of the volunteer being tested and whether the sample was 
taken prior to or after the treatment (in studies II-III). The dysplasia in AKs was graded using a three-step 
grading system, where grade I was mild, grade II intermediate and grade III severe dysplasia (Cockerell 
2000).  
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In addition to HE-stainings, in study III, paraffin-embedded material was used for p53 
immunohistochemistry. The used method detected the overall p53 expression without distinguishing between 
mutant and wild-type p53. The protocol was optimized for diagnostic purposes. The tissue was made into 2 
µm sections. After rehydration, the slides were pretreated by heat-induced epitope retrieval with an alkaline 
buffer. Primary antibody (clone DO-7, Dako M7001, Dako Co., Carpinteria, CA, USA) was diluted 1:200. 
The slides were stained in a Labvision Autostainer with a Dako EnVision detection kit with copper sulfate 
enhancement. The slides were counterstained with hematoxylin. Negative control slides were prepared by 
omitting the primary antibody. The p53 reactivity was quantified by counting the percentage of positive 
nuclei in three consecutive high power fields from the region of highest reactivity, and expressed as the 
average of the three high power fields. We set the threshold of a p53 score >10% to be considered 
pathological. 
5. PHOTODYNAMIC THERAPY 
5.1 Photosensitizers 
Two different photosensitizer precursors were used including methyl-5-aminoleavulinate (MAL 160mg/g, 
Metvix®, Galderma, Paris, France) and 5-aminolaevulinate nanoemulsion (BF-200 ALA, 78 mg/g 
Ameluz®, Biofrontera, Leverkusen, Germany). 
DL-PDT was used in studies III-IV and conventional LED-PDT in study IV; Figure 23 shows the treatment 
protocols.   In study III MAL was compared with BF-200 ALA in DL-PDT. In study V MAL was used in 
DL-PDT and for conventional LED-PDT for AKs to assess the cost-effectiveness of these two treatment 
modalities.  
 
Figure 23. Treatment protocols for DL-PDT and LED-PDT. 
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5.2 Daylight treatment 
In study III we used a randomized split-face design so that one side of the face was treated with MAL and 
the other with BF-ALA with DL-PDT. Before the treatment, identical treatment areas were measured 
symmetrically on the face or scalp and lesions were counted, graded, photographed and drawn on a plastic 
sheet, Figure 24. AKs, ≥6 mm in diameter and equally graded clinically, were bilaterally biopsied prior to 
treatment and at 3 months. Studies were double-blinded i.e. neither the patient nor the investigator assessing 
the outcome measurements were aware of which photosensitizer was used on which side.   
An organic sunscreen (SPF 20, P20®, Riemann & C0. A/S, Hilleroed, Denmark described in detail in 
Wiegell et al 2009, Figure 19) was applied to all the sun-exposed skin areas for 15 minutes prior to 
superficial curettage of the treatment area. The skin was wiped with alcohol (A12T Dilutus 80%,Berner Oy, 
Helsinki, Finland)  prior to application of the sunscreen. No anesthetic was used. The amount of the 
photosensitizers was weighed to achieve a 0.25 mm thick layer on the whole treatment field (mm2 * 0.25 
mg/mm2) on both sides and the area was left uncovered. Daylight illumination was performed 30 min later 
for 2 hours on the hospital balcony and the illumination time was controlled by a nurse.  
At the end of the 2-hour daylight exposure, residual photosensitizer precursors were wiped off, and the 
patients were instructed to spend the rest of the day indoors.  In all DL studies, treatments were postponed on 
very dark or rainy days, or if the temperature was below10̊C.   
 
Figure 24. AK treatment fields, individual lesions and biopsy sites marked on a plastic sheet to help mapping later 
during the follow-up visit. With permission of the patient. 
In the treatment protocol in study IV comparing DL-PDT and LED-PDT in randomized intervidual study 
design differed from that in study III. Three clearly detectable target lesions per patient were chosen for the 
study follow-up. Grade I lesions were given one treatment session and grade II-III lesions two treatment 
sessions 1-3 weeks apart. Before curettage, for DL-group sunscreen (ACO Sun Kids High Protection Sun 
Spray® SPF 30, ACO; octocrylene, ethylhexyl salicylate, diethylamino hydroxybenzoyl hexyl benzoate, bis-
ethylhexyloxyphenol methoxyphenyl triazine, methylene bis-benzotriazolyl tetramethylbutylphenol) was 
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applied for 15 minutes to all the sun-exposed skin areas also including the treatment area. The absorption 
spectrum of the sunscreen had two peaks in the UV-region and only minimally overlapped with the visible 
blue light region, Figure 25. After 15 minutes, the lesions were curettaged under local anesthesia (50:50 
Lidocain c. adrenalin® 10 mg/ml + 10 µg/ml Orion Pharma and Naropin® 7.5 mg/ml AstraZeneca) (gr II-III 
lesions) or without anesthesia (gr I lesions). After curettage, a thin visible layer (approx. 0.25 mm) of MAL 
was applied to the lesional area but not on the surrounding field. The amount photosensitizer of used was 
separately weighed for each patient. No occlusion was used. The patients were instructed to start the daylight 
illumination 30 minutes after leaving the clinic and continue the exposure continuously for a total of 2 hours. 
The treatment time was controlled only by the patients.  
  
  
Figure 25. The absorbance spectrum of an ACO Kids sunscreen. As PpIX absorption peaks are in the visible region of 
light at wavelengths of 410, 505, 540, 580 and 630 nm, this sunscreen is usable in DL-PDT. With permission of Ulf 
Åkerström, ACO. 
5.3 Conventional treatment 
Conventional LED-PDT was used for the comparison with DL-treatment in study IV. Local anesthesia 
(50:50 Lidocain c. adrenalin® 10 mg/ml + 10 µg/ml Orion Pharma and Naropin® 7.5 mg/ml AstraZeneca) 
was used for grade II-III lesions to reduce pain during illumination.  All lesions were superficially curettaged 
to remove crusts prior to application of the photosensitizer. For LED-treatment an approximately 1-mm-
thick-layer MAL was applied to lesional target areas and kept occluded (Tegaderm™+aluminum foil) for 3 
hours. The consumption of photosensitizer was weighed. Afterwards the excess MAL was wiped off.  For 
illumination we used a red-LED lamp (Aktilite® CL16 or CL128, Galderma; peak irradiance at 632 nm, 
Galderma, Paris, France) (Moseley 2005). The lamps were set to give a total light dose of 37 J/cm2 achieved 
in approx. 9 minutes (CL128, average irradiance 65 mW/cm2) or in 7 minutes (CL16, average irradiance 86 
mW/cm2). Primarily, one lamp with a larger 90x190 mm field (CL128) was used but if the lesions were far 
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apart, another lamp (CL16, field 40x50 mm) was used at the same time. If the three target lesions were all far 
apart from each other, the nurse used several illuminations. 
5.4 Efficacy assessment 
In study III treatment efficacy was assessed clinically and histologically by blinded observers at 3 months. 
The responses were evaluated separately for the lesions (lesion complete clearance) and whole treated area 
including assessment of the new lesions (area complete response).In study IV the efficacy was assessed at 6 
months separately for the patients (patient complete response) and for the lesions (lesion complete clearance) 
by a non-blinded observer. 
5.5 Safety assessment 
In both PDT studies (III-IV) the patients were instructed to record pain during and after the treatment using 
theVisual Analog Scale (VAS 0-10).  In study III pain was recorded separately for both treatment sites every 
30 minutes during and every 2 hours after the treatment until 9 p.m., Figure 26. In study III we also assessed 
the adverse reaction at one week by a blinded observer, and patient preference.  
In study IV, the LED-PDT group assessed pain at the beginning, middle, and at the end of each 8-minute 
irradiation session and the DL-PDT group assessed pain every 15 minutes during the 2-hour daylight 
exposure. After the treatments both groups assessed pain once every 30 minutes for 2 hours, and then every 
60 minutes until no pain was experienced. No evaluation for adverse reactions was done. 
 
Figure 26. The Visual Analog Scale for split-face assessment of pain in study III 
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6. COST-EFFECTIVENESS ANALYSIS 
In study IV we assessed the cost-effectiveness of DL-PDT (intervention) compared to LED-PDT (control). 
For the cost-effectiveness analysis (CEA) we calculated the incremental cost-effectiveness ratio (ICER). We 
tested the uncertainty around the point estimate of the ICER with a bootstrapping simulation and presented 
the results using the cost effectiveness plane (CE-plane). 
The probability of a patient’s complete response was estimated by using logistic regression estimation, where 
complete response was defined in cases where 3/3 lesions were completely cleared (value =1) and 
respectively no response if only 0-2/3 lesions were cleared (value=0). Patients’ age and gender, as well as 
treatment group were used as regressors in the logistic models. 
For cost calculations we included the societal costs: monetary valued time-consumption of the nurse (Figure 
27), and the doctor, costs of the photosensitizer, anesthetics and equipment and treatment room rent. We also 
assessed the patients’ cost perspective by valuing patients’ time used for the treatment and patients’ travel 
costs, Table 1 in original article IV.  For valuing the time costs we used the mean monthly salaries of nurses 
(€3089.16) and doctors (resident €4616.1), and for the patients’ the average monthly retirement pension in 
Finland (€1408 in 2012, source: Official Statistics in Finland). 
Costs were assessed for the first 42 patients and the values for each cost item were imputed item by item into 
a multivariate regression model using the following regressors: patients’ age, gender, occupation (outdoors 
vs. indoors work), number of treatment sessions (1-2) and treatment group (daylight vs. LED light) to 
acquire estimated costs for all 70 patients included in the study.  
Costs per complete responder were assessed by dividing the average total cost per patient by the estimated 
probability for a patient’s complete response. 
  
Figure 27. Nurses’ time measurements in study IV  
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7. OTHER STATISTICAL ANALYSES 
Randomizations 
In studies III-IV the randomizations were generated using a web-based validated program (Research 
Randomizer©, http://www.randomizer.org/) that created a random assignment of the treatment sides (study 
III) or treatment protocols (study IV) to randomization numbers. In double-blinded study III the 
randomization result was kept blinded from the investigator who conducted the follow-up visits, from the 
pathologist, and the patients. In study IV we used unblinded protocol. At recruitment neither the patient nor 
the recruiting doctor knew which treatment the patient would receive. The randomization list was printed and 
concealed in an envelope. The envelope was only opened during the treatment visits. 
Sample size evaluation 
No sample size calculations were done for pilot studies I and II. 
 
In study III we calculated the sample size by assuming 30% difference in histological lesion clearance 
between the two studied photosensitizers. Based on Szeimies et al 2012 we used an alpha error of 0.05 power 
of 0.80 and sigma value of 0.26 and this resulted in a sample size of 12 subjects. 
 
 In study IV the sample size was calculated based on costs of the treatments. Based on previous publications 
(Wiegell et al 2008, Rubel et al 2014), we assumed DL-PDT to be as effective as LED-PDT but to be less 
costly due to less time spend at the clinic (Wiegell et al 2008). As no previous data on the costs of DL-PDT 
was available, we used the smallest acceptable difference of 20% between the costs of DL-PDT and LED-
PDT. For the sample size calculator we used an alpha error of 0.05, power of 0.80 and sigma value of 0.3 
giving a sample size of 36 subjects per group.  
 
The statistical tests used in the studies are listed below. P-values <0.05 were regarded as statistically 
significant. 
Wilcoxon’s test 
Study III: per patient half face baseline and clearance, histological baseline and lesion clearance,  reduction 
in histological grading, p53 reduction in immunochemical stains, VAS pain scores (split-face intrapatient 
setting). 
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Fisher’s exact test  
Study III: per lesion baseline characteristics and complete clinical response rates, differences in clinical and 
histological clearance between thin and thick lesions, and decrease in clinical grading. 
Study IV: baseline characteristics, lesion complete clearance rates. 
McNemar’s test 
Study III: the complete histological clearance. 
Pearson's chi-squared test (χ2) 
Study IV patient response. 
Mann-Whitney test 
Study IV: time use, total cost, cost per complete responder and VAS pain scores (interpatient setting). 
Agresti-Coull interval  
Study III: the 95% confidence intervals (95% CI) for clearance rates 
RESULTS 
Study I 
In this study we used HIS for the detection of subclinical borders of LM and LMM. In addition to the 19 
patients described in article I, we recruited four additional patients who are only described in this thesis.  
Altogether we included 23 patients with 23 lesions of which 17 were LMs and six invasive LMMs (Breslow 
thickness range 0.5 and 1.25 mm). The mean clinical lesion size was 2.3 cm2 (range 1.6 cm2 -7.6 cm2).   
The results are shown in Figure 28 (all 23 patients) and in Table 1 original article I (original 19 patients). 
The HIS results were in concordance with the histopathology in 20/23 (87%) cases while in 3/23(13%) cases 
HIS result differed from those assessed histologically. HIS was valuable in 11/23 (48%) cases for detecting 
the lesion borders more accurately than assessed clinically with Wood’s light, of these in eight cases the 
lesions were wider (Figure 29 ) and in three cases smaller than detected clinically. In 10/23(43.5%) cases 
HIS gave no additional information as the lesion borders were similarly delineated clinically, histologically 
and by HIS. In 2/23 cases HIS showed lesion extensions that could not be confirmed by histopathology (false 
positives). In 1/23 case (4.3 %) HIS missed the subtle lesion extension revealed histologically. This study 
was not used to differentiate in situ and invasive LM.  
71 
 
In the two false positive cases LMs were surrounded by benign lentigines (melanosis dermidis) and in one 
case also actinic keratosis which may have complicated not only the HIS interpretation but also the 
histological evaluation. 
After the histopathological evaluation, 6/23 lesions needed re-excision because of the subclinical extension 
of the lesion borders. With the more accurate lesions demarcation with HIS these re-excisions could have 
been avoided. 
 
 
Figure 28. Flow chart results study I. HIS was found useful in 11/23 cases 48% giving more accurate information than 
assessed clinically. In3/23 (13%) of the cases HIS assessed the margins less accurately than a clinician with Wood’s 
light.  
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Figure 29. LM on the lower eyelid, a) a clinical photograph, b) lesion in Wood’s light, c)HIS showing subclinical 
lesion extension (arrow), d) 5-mm clinical excision margins, the lesion continued histologically up to the periphery of 
the superior margin and patient needed re-excision. 
Study II  
Altogether 12 patients with 52 clinical AKs were included in study II.  HIS detected all the clinical AKs, and 
the numerous areas that represented the subclinical lesions. In phase one (6 patients, 41 clinical AKs) we 
detected subclinical AKs using PpIX-fluorescence and used this data as teaching areas for HIS, Figure 30. In 
addition teaching areas for “healthy skin” were taken from clinically healthy-looking, non-fluorescent skin. 
Altogether 27 biopsies were taken from: 1) AKs detected clinically, by fluorescence and HIS (n=6), from 
subclinical AKs detected by fluorescence and/or HIS (both n=6; HIS only, n=9; fluorescence only, n=1), and 
from healthy appearing skin (n=5), Figure 30 and Table 1 in the original article II. From the 27 biopsies 22 
fulfilled the criteria of an AK, and 5 represented healthy skin.   
Of the 22 AKs 6 were clinically detected, and 16 were subclinical. HIS data analyzed by the neural network 
revealed all the clinically detected AKs and all the histologically confirmed 16 subclinical AKs. In 
comparison, fluorescence detection missed 9 of the HIS detected subclinical areas and misdiagnosed one 
area representing healthy skin as an AK, Figure 31. 
As the neural network needed pre-defined teaching areas we had to run the data again in two cases after 
receiving the histopathological reports. In one case it was noticed that one area assumed to be healthy 
histologically represented an AK and this area had incorrectly been used as a teaching area for HIS. The data 
was reanalyzed by using another healthy looking skin area but the diagnosis was not confirmed by histology 
73 
 
(group 1, patient 1). In another patient the fluorescent skin area revealed histologically not to fulfill criteria 
of an AK and the data was re-analyzed using this area as a teaching area for healthy skin (group 1, patient 3).  
In phase two (6 patients, 11 clinical AKs) no PpIX fluorescence was used and we took the hyperspectral 
images from naive skin without marking the lesions and again after marking lesion borders. As we wanted to 
conduct the analyses without teaching areas, we used the unsupervised linear signal unmixing method for 
analyzing the data. We calculated the abundance images by searching the spectra derived from a typical 
biopsy confirmed AK (Fig 4 in the original article II), and calculated the abundance images based on this 
spectra, Fig 5 in original article II. Afterwards we took 6 biopsies, one from each patient to confirm the 
diagnosis. We then rerun the data using a white background reference and identified the mean pure AK 
spectra (end-member) of an AK and healthy skin, Figure 32. After completing the study eight of 12 patients 
received daylight-PDT and twoLED-PDT. Two patients received LN cryotherapy for milder skin damage 
(both in phase two).   
 
Figure 30. Neural network teaching with PpIX fluorescence. a) Clinically clearly detected AKs marked with a black 
pen, b) fluorescence in Wood’s light (clinical lesion thick arrow, subclinical thin arrow), c) fluorescent areas marked 
with a blue pen, d) teaching areas for HIS: healthy appearing skin (green), sick areas (red; clinical and subclinical AK) 
e) Neural network analysis showing field cancerized areas red, f) site of the punch biopsies to confirm the results. 
Results presented with the permission of the patient. 
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Figure 31. Results Study II, phase two. 
 
Figure 32.End members of AK and healthy skin, mean reflectance (converted with white reference) patients 1-6 (phase 
2). Wavelength (nm), reflectance (relative). 
 
Study III 
Of the 14 patients included 13 completed the study.  One patient was withdrawn from the study due to health 
problems not related to the study. The patient characteristics are shown in Table 6. The patients were treated 
in a split-face randomized design so that 84 AKs (grade I, n=61, grade II-III, n=23) were treated with BF-200 
ALA and 93 AKs (grade I n=73, grade II-III, n=20) were treated with MAL. Altogether 26 biopsies were 
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taken, one from each site, prior to treatment and at three months. No difference was found in the baseline 
between BF-200 ALA and MAL groups in lesion count or clinical grading (p= 0.524), or in histological 
grading (p=0.157), Tables 1and 2 in the original article III.  
When assessed clinically at 3 months, in a per patient half-face analysis BF-200 cleared more thin lesions 
than MAL (p=0.027) but no difference was found for thicker lesions (p=0.564) or in lesion total clearance 
(p=0.110), Table 2 in original article III. In per lesion analysis, BF-200 ALA had completely cleared 71 of 
84 AKs (84.5 %; 95% CI 75.2-90.9%) and MAL 69 of 93 (74.2 %; 95% CI 64.4-82.1%) AKs, p=0.099, 
Table 7. Of the residual lesions 17.4% in BF-200 ALA group and 25% in MAL group were in partial 
response i.e. the grade had diminished by one or two grades compared to the baseline. No difference was 
found between BF-200 ALA and MAL in reduction of the lesion grading (p=0.065). Thicker lesions (gr II-
III) responded equally with thin lesions (gr I) in both groups when treated twice (p=0.330 and p=1.00 for BF-
200 ALA and MAL), Table 8, Figure 33.  
Altogether four new lesions appeared during the follow up in three areas treated with BF-200 ALA and eight 
in three areas treated with MAL (p=0.379). One patient developed new lesions on both treatment sites. We 
conducted an experimental outcome analysis of area complete response including both the clearance of the 
baseline lesions and appearance of the new lesions clearly separate from these. The area complete response 
was 79.8% for BF-200 ALA and 65.6% for MAL, p=0.044, Table 7.  
Histologically, the complete clearance rates were 61.5% (8 of 13) for BF-200 ALA and 38.5% (5 of 13) for 
MAL (p=0.375) with all grades responding equally (p=1.000 in BF-200 ALA and p=0.103 in MAL group), 
Table 3and Fig 3 in original article III.  Reduction in histological grading was significant in both groups 
(p=0.005 in BF-200 ALA and p= 0.017 in the MAL group, p=0.187 between BF-200 ALA and MAL).   
Positive p53 expression (>10%) was obtained in 13/13 samples in BF-200 ALA group and in 10/13 samples 
in MAL group before treatment, Fig 4, original article III. Of the positive samples in the baseline, p53 was 
completely cleared to <10% in 3/13 in the BF-200 ALA group and in 5/10 in the MAL group after the 
treatment.  In one case in the BF-200 ALA group and in two cases in MAL group the p53 expression was 
increased compared to the baseline and in one case in BF-200 ALA group and in two cases in MAL group 
p53expression stayed at the baseline level. The mean reduction in p53 expression was 54.4% (p=0.003) in 
the BF-200 ALA group and 33.7% (p=0.019) in the MAL group, p=0.552, Figure 34. 
Both BF-200 ALA and MAL treatments were overall painless with a mean maximal pain score of 2.1 (range 
0.2-8.6) and 2.0 (range 0.2-8.6) with no significant difference between the groups. One patient had high pain 
scores on both sites 4 hours after the first treatment but not the second treatment. This patient had not 
received any previous AK treatments and had severe photo damage with a total of 16 AKs (7 on BF-200 
ALA site and 9 on MAL site). When assessed by a blinded observer one week after the first treatment, seven 
patients had more severe reactions (erythema, crusting) at the site treated with ALA, five patients had more 
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severe reactions at the MAL site and one patient showed no difference between sites. Six patients expressed 
no preference for further treatment while four favored MAL and three, BF-200 ALA. 
 
 
 
 
 
Figure 33. Results Study III 
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Table 7. Results studies III-IV 
 
 
 
 
Table 8. Lesion clearance thin vs. thick lesions, studies III-IV. 
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Figure 34. p53 expression level prior to treatment and at 3 months study III. 
 
Study IV  
Of the 73 randomized patients 70 completed the study, Fig 2 in original article IV. Patient characteristics are 
shown in Table 6. Altogether 210 lesions were treated 105 (gr I, n=93, gr II-III n=12) in 35 patients with 
LED-PDT and 105 (gr I, n=92, gr II-III, n=13) in 35 patients with DL-PDT, p=0.46, Table 7. Seven patients 
in both groups received two treatments for grade II-III lesions and 28 one treatment for grade I lesions. 
When assessed at the patient level the complete response rates (3/3 lesions cleared) were 24 of 35 for LED-
PDT and 15 of 35 for DL-PDT, p= 0.030. Lesion complete clearance rates were 94 of 105 (89.2%, 95% CI 
82.1%-94.2%) for LED-PDT and 76 of 105 (72.4%, CI 95% 63.1%-80.1%) for DL-PDT with LED PDT 
being significantly more effective, p=0.0025. When assessed separately for grade I lesions clearance rates 
were 82/93(88%) and 68/92(73.4%) and for grade II-III lesions12/12(100%) and 8/13(61.5%) for LED-PDT 
and DL PDT, respectively (p=0.015 and p=0.039), Table 8.  
We estimated the probability for a patient’s complete response to be 0.429 (95% CI 0.4140 – 0.4432) for 
DL-PDT and 0.686 (95% CI 0.6736 – 0.6978) for LED-PDT. Thus, the incremental efficacy value was          
-0.257. The imputed mean total costs per patient were €132 (95% CI 111.3-152.6) for DL-PDT and €170 
(95% CI 126.0-213.5) for LED-PDT, p=0.022. The costs per item are specified in the attached original 
article IV, Table 1.  The incremental costs (savings) were -38 euros. The results suggest that DL-PDT is 
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associated with an incremental cost saving of €147 with a decremental probability to get healed of -0.257, 
Table 2 in original article IV.  The CE-plane showed ICER results reliable i.e. the use of DL-PDT would 
lead to costs savings but also lower the probability for a patient’s complete response, Fig 2 in original article 
IV. 
The costs per complete responders were €248 for LED-PDT and €308 for DL-PDT (p=0.004).  
DL-PDT was less time consuming for the nurse (median 51 minutes vs. 78 minutes per treatment, p=0.003) 
and for patients (median 194.5 min vs. 271 min, p<0.0001) compared to LED-PDT. DL-PDT was 
significantly less painful (mean maximal pain value 1.53, range from 0.1 to 6.0) compared to LED-PDT 
(mean maximal pain value 4.36, range from 0.3 to 8.4) despite the use of local anesthetic for grade II-III 
lesions, p<0.001, Figure 35.  
 
Figure 35. Pain values LED-PDT vs. DL-PDT. DL-PDT was significantly less painful (mean maximal pain 1.53 vs. 
4.36, VAS 1-10, p<0.001) despite the use of local anesthetic for thicker lesions. 
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DISCUSSION 
The novel hyperspectral imaging system (HIS) was found to be useful in the delineation of ill defined LM 
and LMM borders. It did so more accurately than could be clinically detected by Wood’s light for both tasks, 
and in the detection of subclinical AKs (studies I and II) .Compared to currently available techniques, HIS 
offers a large FOV (12 cm2), which is suitable for investigations of large skin areas rapidly (seconds) 
followed by quick data processing and classification of the spectra. The results are obtained from abundance 
maps representing end-members i.e. pure spectra of affected areas and healthy skin. As these pilot studies 
have produced promising preliminary results, further studies are warranted to qualify the optimal 
mathematical algorithms and to assess the sensitivity and specificity of the method for diagnostic use.  
The hyperspectral system used detected diffuse reflectance and thus provided information about light’s 
scattering and absorption properties in the skin. While light scattering is mainly caused by cells in the 
epidermis and collagen in the dermis, absorption is mainly dominated by light absorption from hemoglobin 
and melanin. Changes in the skin morphology during carcinogenesis leads to changes in the skin’s optical 
properties (Rajaram et al 2010). As far as we know, no current studies use diffuse reflectance hyperspectral 
imaging for the detection of AKs or LMs.  
In study I HIS was used for differentiating subclinical LM borders from surrounding skin.  We found HIS 
useful in 11/23 cases where lesions were either wider (n=8= or smaller n=3) than could be clinically 
detected. In six cases HIS revealed subclinical extensions which could have led to avoidance of the re-
excision. In three cases where the LMs were smaller than clinically detected HIS could have been helpful in 
saving tissue in cosmetically sensitive facial areas.  
As the experimental study proceeded, the protocol was improved. Six lesions were directly operated on with 
wide excisions after the HIS imaging. As the study proceeded, we changed the protocol so that the HIS 
findings were more easily mapped with the histological findings. We found targeted biopsies of the lesion 
borders useful for this purpose. Another useful approach was to excise the lesion directly from its clinical 
border and then excise the margin as a separate circumferential strip.  We used vertical sectioning of the 
samples. The use of horizontal sectioning and/or MMS would have led to an even more accurate comparison 
of the HIS finding and histology. In the cases of suspected subclinical extension, extra cuts were prepared for 
the specific HIS detected areas if subclinical extensions were not seen in the initial samples. The presence of 
benign melanosis or an AK in the vicinity of the LM border complicated the delineation of the LM borders in 
the two false positive cases but they also might have complicated the interpretation of the histologic samples. 
However, we will have to further develop our analysis process to differentiate spectral data from LMs and 
other skin lesions like pigmented AKs and lentigines more accurately. We are currently working on finding 
the specific spectra for the common lesions of photo-damaged skin for their accurate separation 
(Neittaanmäki-Perttu et al 2014, unpublished data).  
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The current methods for surgical margin control (SSE, MMS) require resources (technicians, pathologists, 
and surgeons) and the high degree of expertise required makes the process time-consuming and often 
requires multiple office visits. Based on these facts here is an urgent need for a noninvasive tool for pre-
surgical margin control and for follow-up examinations. One of the currently used techniques for aiding 
detection of LM borders is fluorescence detection with Wood’s light (Paraskevas et al 2005,, Kimyai-Asadi 
et al 2007, Hazan et al 2008).  In our study, we used Wood’s light for the detection of lesion borders as we 
routinely use it in our daily practice. We did not compare the margins seen by the unaided eye and those seen 
under Wood’s light. Our result showed that in 11/23 cases HIS was more useful than a clinician using 
Wood’s light for detection of the lesion borders. Other techniques for this purpose include dermatoscopy and 
reflectance confocal microscopy. In addition, multispectral analyses like Siascopy (Moncrieff et al 2002) or 
HD-OCT (Boone et al 2013) could potentially be used for LM border detection but as far as we know no 
studies of this currently exist. A limitation in our study is that we used dermatoscopy only as a diagnostic aid 
and not for lesion border detection. This would have been interesting as dermatoscopy can accurately be used 
for detection of LM borders (Robinson JK 2004).  RCM is a promising tool for mapping the LM borders 
(Guitera et al 2013). However, the small FOV makes the mapping of the wide areas slow and currently the 
costs of the device limit its availability. Both dermatoscopy and RCM are strongly user-dependent and thus 
not comparable with HIS.   
In study II we used MAL fluorescence detection to find subclinical incipient lesions for teaching areas in 
order to find areas that could be use to assess HIS. 10/16 of the subclinical lesions detected by HIS were not 
detected by fluorescence. In addition one fluorescent lesion was found to be sun damaged skin and not AK. 
A limitation in our study is that we used fluorescence detection by Wood’s light with visual inspection 
instead of using a more sensitive CCD camera that corrects the images for the skin’s auto fluorescence (van 
der Beek et al 2012). Fluorescence detection is a common method for subclinical AK detection even though 
it lacks specificity as inflammatory skin diseases also accumulate PpIX (Smits et al 2005). In addition it is 
time-consuming, due to the hours of photosensitizer occlusion needed prior to imaging (van der Beek et al 
2012). In our study 6 of the 7 fluorescence detected biopsied lesions were confirmed as AKs, which shows 
the method has a high specificity. However 10 of the 16 histologically confirmed lesions were not brightly 
fluorescent but were seen in HIS analysis which shows HIS may be more sensitive in the detection of these 
lesions from sun-damaged skin. In our study the HIS detected subclinical lesions were histologically verified 
as fully developed AKs.  The histologic diagnostic criteria for early subclinical AK are not clear. Sun-
damaged skin often represents many histological characteristics of an AK and it has been suggested this 
presents the very early stages of AKs (Einspahr et al 1997).  A limitation of study I is that in phase two 
where linear signal unmixing was used we took only one biopsy per patient to verify the diagnosis and did 
not take biopsies from the surrounding skin as we did in phase one where we used the supervised neural 
network method.   
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We found that HIS accurately detected yet invisible premalignant changes in the skin. However, it should be 
noted, that the specificity of the method was not studied. Instead of differentiating AKs from different skin 
conditions, this pilot study concentrated on the detection of AKs from surrounding healthy skin for early 
detection of the premalignant changes. As AKs are characterized in the superficial part of the skin and 
diffuse reflectance also detects the dermal part, diffuse reflectance may not be specific enough for detecting 
optical differences derived only from the superficial part of the skin.  From the mean spectrum of AK and 
healthy skin (Figure 31) it can be concluded that the difference is mainly seen at 500-600 nm where 
hemoglobin dominates the spectra. Thus the difference between AK and normal skin might likely be due to 
different amounts of blood volume, which can also be a feature of many skin conditions other than AK. 
Thus, we also experimentally tested imaging facial eczema with HIS and found that the spectrum differed 
from that of an AK (Neittaanmäki-Perttu et al 2015, unpublished data). Currently we are working on a new 
mathematical modeling based approach to differentiate chromophore-specific parameters from the HIS 
images. These parameters are retrieved from a mathematical reflectance model of the skin. When 
experimentally testing this new approach to eczema we found clearly more blood volume in the skin for 
eczema areas than in areas containing an AK and also detected differences in other skin chromophores 
(Neittaanmäki-Perttu et al 2015, unpublished data).  The specificity of the HIS findings should be given 
more attention in future studies.  
A device, which to our knowledge is not yet commercially available, which combines the measurement of 
diffuse reflectance (350-700 nm) and laser-induced fluorescence in vivo (FOV 6.5 mm in diameter), and 
provides automated classification was able to separate AK from cSCC with 100% sensitivity and 50% 
specificity and detected significant spectral differences between lesional and normal skin (Rajaram et al 
2010). This device, unlike HIS, fails to produce images and was not used for the detection of subclinical 
lesions. Dermatoscopy can be used for the detection of clinical AKs and might help but no current criteria for 
subclinical AKs exist. RCM accurately detects clinical and subclinical AKs but it is time consuming due to 
small FOV, it is also expensive and highly-user dependent and thus not widely used for this indication 
(Ulrich M et al 2010, Guitera et al 2013).  HD-OCT is another promising tool for the detection of AKs in 
their early phases and also for monitoring treatment efficacy (Maier et al 2013). It also offers the advantage 
of both horizontal and vertical imaging, but like RCM it has a small FOV (1.8 x 1.5 mm) and is user-
dependent which makes observations of large areas time-consuming. Conventional OCT with larger FOV 
(6x6mm) has too poor a resolution for the visualization of AKs (Maier et al 2013). Raman spectroscopy 
provides point based spectral information of small areas (diameter 3.5 mm) and does not provide images and 
thus can not be compared with HIS. In comparison with the other methods Raman spectroscopy uses 
automated classification of the acquired spectral signals. It was only recently that multispectral Siascopy has 
been used for the detection of different chromophores in sun-damaged skin but the study was not used to 
detect AKs (Stimpfle et al 2014). The imaging depth and resolution of our HIS are comparable with that of 
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multispectral devices but the analyzing technique detects characteristics that are beyond the single pixel 
resolution. In addition, the FOV is larger. 
In studies I-II we used two different analyzing processes: supervised neural network analysis and the 
unsupervised linear spectral unmixing method. These methods are detailed elsewhere (Pölönen et al 2013). 
As neural network analysis needs pre-defined teaching data and is thus user-dependent, we have found 
spectral unmixing to be more useful. As we noted in study II, defining incorrect teaching areas could lead to 
misclassification of the data.  A limitation is that in study II we did not initially use a white reference for 
data normalization and thus the AK spectra in original article II, Fig 4 differs from that shown in this thesis 
(Figure 31).  Further studies should concentrate on the diagnostic accuracy of these methods and combining 
spectra of different lesions apparent in sun damaged skin as well as inflammatory processes. Multicenter 
studies are warranted to validate the method. A future aspect should also include a cost-effectiveness 
analysis for HIS. 
Our studies III-IV are the first DL-PDT studies conducted in Finland and the first studies to use 
photosensitizers other than MAL in this manner.  Our results of DL-PDT for grade I-III AKs show lesion 
clearance rates of 84.5% for BF-200 ALA, 72.4-74.5% for MAL. However, the clearance rates for LED-PDT 
were higher resulting in 89.2% complete lesion clearance. Interestingly the lesion clearance rate for BF-200 
ALA DL-PDT approached the clearance rate of MAL LED-PDT. As the nanoformulation enables the use of 
low concentrations of 5-ALA, the costs of BF-200 ALA are significantly lower than those of 16% MAL (199 
vs. 398 e per 2g according to Biofrontera, Germany). Currently BF-200 ALA is approved but not on market 
in Finland, but it can be purchased for special purposes.  
When compared to previous DL-PDT studies, all conducted with MAL, our lesion clearance rates are 
comparable with the earlier studies conducted in Denmark, Norway and Sweden showing lesion clearance 
from 75.9 to 79.5% (mostly thin AKs ) (Wiegell et al 2008, 2009, 2011, 20121).  A recent Australian 
multicenter DL-PDT study reached higher clearance rates of 89.2% but included only thin lesions in the 
analysis (Rubel et al 2014). Our slightly lower efficacy rates compared to previous studies conducted in 
Europe for DL-PDT could be explained by the fact that we treated lesions of all grades and used a longer 6 
month follow-up period in study IV compared to most of the DL-PDT previous studies, which reported only 
the 3-month clearance. In addition, in study IV the behavior of the patients (e.g. the illumination time) was 
not controlled reflecting the situation in real life practice. 
In a recent study using BF-200 ALA in a controlled simulation of daylight treatments the clearance rates 
were higher (93% lesion clearance and 75% patient response) than seen in previous DL-studies (Kellner et al 
2014). In a simulated DL- room the irradiance can be controlled and treatment can be implemented all year 
round. However the retrospective studydesign questions the counting and mapping of the lesions during the 
study and there is a need for further prospective controlled trials. DL-PDT can not be implemented during 
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the dark winters in northern countries (Wiegell et al 20122) but simulated DL-rooms could eliminate this 
limitation.  
The clearance rates for thicker lesions in DL-PDT have previously been reported to be 61.2% for grade II 
and 49.1% for grade III AKs (Wiegell et al 20121). We used repeated treatment (two sessions 1-3 weeks 
apart) for thicker grade II-III AKs and achieved higher clearance rates, 76-5-88% for MAL and 78% for BF-
200 ALA after 3 months. We found no significant differences in the lesion clearance rates for MAL or BF-
ALA PDT as a function of lesion thickness. However, LED-PDT significantly cleared more thin and thick 
lesions than DL-PDT. 
The patient complete response rate was reported in our study IV for MAL-DL-PDT (42.9%) and for MAL-
LED-PDT (68.6%) at 6 months. No previous DL-PDT studies had reported the clearance rates at the patient 
level. Previously, the complete patient clearance rates for MAL-LED PDT varied from 46% after one month 
(Moloney et al 2007) to 59.2%-68.4% after 3 months (Pariser et al 2008, Zane et al 2014) and to 55.2% after 
one year (Zane et al 2014). Our results for LED-PDT support these findings. Due to the intra-individual 
split-face design in study III using DL-PDT it was not possible to assess patient complete response rates. 
However, we evaluated the data in per-patient half-face analysis. In addition, we reported an experimental 
value for area complete response including cleared lesions and also the newly appeared lesions on the whole 
treated field during the 3-month follow-up. Complete area clearance rates were 79.8% for BF-200 ALA and 
65.6% for MAL.  The area complete response rates had not been reported in previous studies.  The 
appearance of new lesions i.e., the preventive effect is rarely reported. Wiegell et al reported a mean of 2.8 
new lesions per patient during a 3-month follow-up after DL-PDT (Wiegell et al 20121). We found altogether 
8 new lesions in MAL treated sites and 4 in BF-200 ALA treated sites in 13 patients after 3 months in study 
III. In the future, more attention should be paid to the preventive effect of field directed treatments and also 
more attention should be paid to clearance reports at the patient level. 
The spontaneous regression rates for AKs vary between 15-63% after one year, but remission rates are also 
high (15%-53%) (Werner et al 2013). No placebo-controlled DL-PDT trials currently exist. In LED-PDT 
studies placebo treatment with curettage leads to significantly lower clearance rates (Table 5).  It is obvious 
that there is a need for a placebo-controlled DL-PDT trial. 
To our knowledge, our study III is the first to report the histological clearance rates for DL-PDT. BF-200 
ALA showed a trend towards higher histological efficacy than did MAL with 61.5% vs. 38.5% complete 
histological clearance rates. We also assessed the p53 expression from the biosy samples. Sun-exposed skin 
expresses higher level of p53 (approx. 1% for skin not adjacent to AKs and up 10% for AK-adjacent skin) 
than non-sun-damaged skin (approx.0.1%), but at a rate lower than that seen for AKs (approx.30%) even 
though there is a great heterogeneity between individuals (Einspahr et al 1997). Different treatments and 
radiotherapy can cause reactive atypia and elevated p53 expression levels (Aron M et al 2013). Thus, we set 
the 10% threshold for “normal” p53 expression. At the baseline, we found positive (>10%) p53 expression in 
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23/26 (88.5%) of the pre-treatment skin biopsies. Compared to the baseline,  p53 expression reduced by 54% 
with BF-200 ALA and by 34% with MAL. Previously, a single conventional MAL-PDT session cleared AK 
dysplasia completely in 55%, and showed significant, but not complete reduction in p53 expression in 50% 
of the samples, indicating that a single treatment session is not effective enough to completely clear the 
actinic damage (Bagazgoitia et al 2011). Another group took biopsies from healthy-appearing skin field 
cancerized areas before and three months after three separate sessions of MAL-PDT. Histological findings of 
keratinocyte atypia and extent decreased significantly but p53 expression showed only a non-significant 
trend towards reduction. This was thought to result from the biopsy sites being on normal appearing-skin and 
thus having lower baseline expression of p53. Also a significant increase in collagen deposition, and 
reduction of solar elastosis were seen indicating that PDT also reduces signs of photoaging and offers 
excellent cosmetic outcome (Szeimies et al 2012).  Our results show a significant reduction in histological 
signs of carcinogenesis after DL-PDT. Also, the reduction in p53 expression indicates a reversal in the 
carcinogenic process, and thus that DL-PDT can be used as well in a preventive manner. The fact that p53 
expression did not decrease in all the studied samples might be due to further cumulative UV exposure, as 
we cannot confirm that the patients followed the instructions for photoprotection after the treatment. We 
have continued the follow-up for up to 12 months in order also to assess the long-term effects histologically 
(Neittaanmäki-Perttu et al 2015, unpublished data). A limitation of study IV was that we did not confirm the 
AK diagnosis by biopsies or assess the histological clearance. However, in the other studies (II-III), we 
biopsied clinically detected AKs in each patient and the accuracy of the clinical diagnosis was 100% as all 
the lesions biopsied as AKs under clinical diagnosis showed signs of AKs also histologically. 
We used a thinner 0.025mm-thick  layer of the  photosensitizers in our DL-PDT studies than previously 
reported (1 mm) (Wiegell et al 20122).It is possible that in DL-PDT where PpIX is activated during its 
development, lower amounts of PpIX are needed, and thus lower concentrations and thinner layers of the 
photosensitizers can be used than in conventional treatments. Both could significantly reduce the costs of the 
treatment. Only one study used lower MAL concentrations for DL-PDT in humans and found that MAL8% 
is as effective as MAL16% in DL-PDT of AKs (Wiegell et al 2009). The effect of the layer thickness had not 
been reported earlier. Further studies are warranted to assess the optimal layer thickness and photosensitizer 
concentration in order to lower the costs without affecting the efficacy. 
In both studies considering DL-PDT (III-IV) the mean maximal pain values were low and in study IV 
patients treated with LED-PDT reported significantly higher pain scores. This is in accordance with the 
previous studies, which had reported lower pain values for DL-PDT compared to LED-PDT due to 
continuous activation of PpIX (Wiegell et al 2008, Rubel et al 2014). Our pain values are not directly 
comparable as the other DL-studies report pain values using a numerical 1-10 scale while we used VAS. The 
mean maximal pain scores during DL-treatment were slightly higher in study III than in study IV. This 
might be due to the local anesthetic used for the thicker lesions in study IV.  In study III, one patient 
reported severe pain (VAS>8) on both sites 4 hours after the treatment. It is possible that the patient did not 
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follow the instructions to stay indoors after the treatment or stayed outside for longer than instructed. During 
the second treatment, the same patient reported the pain scores <1 on both sides during the whole treatment 
day. A similar effect of increased pain was reported earlier when the illumination time was not controlled 
(Wiegell et al 2009). Also another patient in study III reported high (approx. VAS 9) pain scores on both 
sites during the second treatment (at 1.5 hours) even though the patient experienced almost no pain during 
the first treatment. This might be due to direct sunlight during the second treatment as during the first 
treatment it was partly cloudy and the temperature was two degrees lower. However, in both cases no 
difference between the treatment sides was reported. In study IV we used local anesthetic in both groups 
mainly to reduce pain during the LED-illumination. Due to this, the mean maximal pain values in our LED-
group were lower than reported previously (Wiegell et al 2008). However, again the numbers are not directly 
comparable due to different scaling (numerical 1-10 vs. VAS). One patient in the LED-group had to spend 
the night in the hospital because of the pain in the LED-treated areas after the second treatment. This patient 
received three illuminations due to the location of the lesions on different sides of the face. The need for 
more than a single illumination is not unusual in patients with severe wide spread photodamage. In these 
patients, DL-PDT should be considered to increase the tolerability of the treatment. 
A limitation in our study III is the limited follow-up period of 3 months and a relatively small sample size. 
We have assessed the efficacy of study III again at 12 months (Neittaanmäki-Perttu et al 2015, unpublished 
data). In study IV the follow-up period was longer, i.e., 6 months, which might have caused the slightly 
lower clearance rate for DL-PDT in this study. A further limitation is that the sample size in study III was 
calculated based on histological lesion clearance, which was assumed to be a continuous variable based on a 
previous study (Szeimies et al 2012). In our study the histological clearance was assessed using a three step 
grading system. Another limitation in all of our DL-PDT studies (III-IV) is that we did not record the light 
dose during the daylight illuminations. This would have been interesting because the strength of the 
irradiance may change with weather conditions. However, it has been suggested that the minimum effective 
light dose of 8 J/cm2 can be reached in northern countries like Finland (latitude 64 ̊ N) until mid-September 
(Wiegell et al 20122). The study treatments implemented during summers 2011-2013 (studies III-IV) 
showed very similar efficacy for MAL, a photosensitizer used in both DL-PDT studies, which reflects the 
repeatability of our results. In study (IV) we used home-based setting and thus did not monitor the time 
patients spend outside for illumination. In this study the clearance for MAL was slightly lower (72.4%) than 
in study III (74.2%) where the 2-hour-illumination was monitored by a nurse. This difference may also be 
due to the longer follow-up period (6 months) than in other two studies (3 months).  Patient compliance is 
important when using DL-PDT. However, this is not such a problem as with most of the topical AK 
treatments with long application times at home and prolonged adverse reactions. Another limitation is that in 
study IV we did not use blinded assessment of the efficacy as we did in study III. 
DL-PDT is well tolerated. Adverse reactions were recorded by a blinded observer in study III. We found no 
difference in adverse reactions after DL-treatment between MAL (more severe reactions on the 5 MAL 
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sides) and BF-200 ALA (more severe reactions on 7 BF-200 ALA sides) (study III). A limitation is that we 
did not assess the adverse reactions in study IV comparing LED-PDT and DL-PDT. However, it has been 
shown that DL-PDT is better tolerated than LED-PDT (Rubel et al 2014). When we assessed patient 
preferences in study III six patients expressed no preference for further treatment while four favored MAL 
and three, BF-200 ALA. A further limitation is that we did not include evaluation of the cosmetic outcome. 
However, it is known that both LED-PDT and DL-PDT result in excellent cosmetic outcomes (Rubel et al 
2014).   
As showed in study IV, DL-PDT required less of the nurse’s and patient’s time and was less costly compared 
to LED-PDT.  However, DL-PDT with MAL was less effective compared to LED-PDT with MAL. In CEA, 
DL-PDT with MAL showed to provide less value for money compared to LED-PDT with MAL.  
In our own experience it is much more convenient and practical to use DL-PDT. In conventional-PDT, the 
size of the treatment area is limited due to the size of the lamp (Moseley 2005), and due to pain. With DL-
PDT the treatment is painless which enables treatment of large areas simultaneously. A limitation is that we 
did not include the assessment of pain and QALYs in our CEA analysis.  As DL-PDT requires less time at 
the clinic, more patients can be treated and the illuminations are not limited by the number of available lamps 
or nurses. DL-PDT is also suitable for private practices with short visiting times.  
The strengths of our cost-effectiveness study (IV) were that we used a prospective study design and included 
accurate costs of the treatments. Most of the cost-effectiveness studies of AK treatments are funded by drug 
companies and use estimated and modeled values. Conventional PDT has been considered a “cost-effective” 
therapy for AKs, with total cost of care of €381 per patient and €58 per lesions including pretreatment visit, 
treatment costs and follow-up visits (Annemans et al 2008). To our knowledge this conclusion can not be 
drawn as the study failed to compare two interventions, which is the principle of any cost-efficacy 
evaluation. The study was funded by Galderma. In comparison, the estimated costs for destructive treatments 
were 131 USD per one AK and 258 USD for ≥15 AKs (Warino et al 2006).  In a non-sponsored study, the 
costs per complete responder were €363 for MAL-PDT and €379 for LN cryotherapy including the cost of 
yearly re-treatments, and also valuing the cosmetic-outcome in a decision tree model (Caekelbergh et al 
2006). When compared in a decision tree model estimating quality –adjusted life years (QALY) vs. the cost 
of the treatments over one year, imiquimod was implied to be more cost-effective than MAL-PDT. The 
authors had connections with MEDA (Wilson 2010). On evaluating patient complete response and cosmetic 
outcome in a decision-tree model, MAL-PDT was found to be more cost-effective compared to imiquimod 
and 5-FU (Muston et al 2009). The limitations were that the model only included the price of the topical 
drugs and authors had connections to Galderma. Even though more expensive, MAL-PDT showed equal 
cost-effectiveness compared with imiquimod and 5-FU when evaluated in a decision tree model (Neidecker 
et al 2009). As far as we know, in addition to our study, there is only one prospective non-sponsored head-to 
head cost-effectiveness study comparing AK treatments.  In this Italian study MAL-PDT was more cost-
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effective compared with diclofenac+hyaluronic acid gel (DHA) with the costs per complete patient response 
of €566.7 and €1026.2 for MAL-PDT and €595.2 and €2295.2 for DHA at 3 and 12 months (Zane et al 
2014). The Italian researchers failed to use appropriate sensitivity analysis for verification of their results. 
Our results can not be directly compared with the previous studies as we included the accurate costs in a 
head-to-head design but did not include the costs of further treatments or quality of life (QALY) aspects.  
A limitation of our study IV is that we used a treatment method targeted to lesions and did not record the size 
of the lesions. If we had instead targeted the whole field, the consumption of the photosensitizer and thus 
cost in both treatments would have been higher. In addition this might have affected the time used by the 
nurse, and thus the cost of the LED-treatment. This protocol would have enabled us to record the appearance 
of new lesions and thus also to record the preventive effect. Further studies comparing the cost-effectiveness 
of lesion targeted vs. field targeted PDT are warranted. In our DL-studies we used thinner layers of 
photosensitizers than instructed for conventional treatment. This showed comparable efficacy values with 
previous treatments. However the results should be confirmed in larger trials comparing different thicknesses 
of the photosensitizers. The use of lower amounts of the drug could lead to a more cost-effective treatment 
protocol. In addition the use of novel and possibly more effective formulations of photosensitizers could 
further increase the cost-effectiveness of PDT. These subjects require further studies. 
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CONCLUSIONS 
 The hyperspectral imaging system (HIS) can be used for the detection of subclinical lentigo maligna 
(LM) and lentigo maligna melanoma (LMM) borders and thus could reduce the number of re-
excisions 
 HIS offers a practical non-invasive tool for the detection of incipious actinic keratoses (AK) on field 
cancerized skin 
 Further studies are warranted to validate the mathematical method for HIS analysis 
 As HIS was used to separate lesions from surrounding sun-damaged skin, further studies are 
warranted to separate the spectra of different skin tumors for diagnostic use 
 Daylight photodynamic therapy (DL-PDT) is a well tolerated and effective treatment for actinic 
keratoses (AK) 
 Also thicker grade II-III AKs can be treated with DL-PDT with repeated  treatment sessions 
 Compared to conventional LED-PDT, DL-PDT is less painful and more convenient to use as it 
requires significantly less patients’ and nurses’ time 
 Although DL-PDT using methylaminoleavulinate (MAL) can be implemented with lower costs, 
conventional LED-PDT with MAL resulted in higher patient complete response rates. In an 
incremental cost-effectiveness analysis, MAL-DL-PDT provided less value for money compared to 
MAL-LED-PDT. 
 The novel photosensitizer formulation 5-aminolaevulinic acid nanoemulsion (BF-200 ALA) can be 
used with daylight activation  
 In the treatment of AKs, DL-PDT with BF-200 ALA  showed a trend towards improved efficacy 
compared to MAL-DL-PDT 
 At three months after DL-PDT, the complete histological clearance was seen in 61.5% of the BF-200 
ALA-treated AKs, in 38.5% MAL-treated AKs 
 Reduction in p53 was seen with both photosensitizers implying the reversal of the carcinogenesis 
process with DL-PDT 
 In DL-PDT, a thin 0.25-mm -thick layer of the photosensitizer (compared to the recommended 1-
mm-thick layer used in conventional PDT) seems enough with both MAL and BF-200 ALA, which 
could  lower the treatment costs 
 The novel nanoformulation, BF-200 ALA, enables the use of lower photosensitizer concentrations, 
which could further reduce the costs of the treatment 
 This thesis reported relatively short term clearance rates (3-6 months) and thus long-term efficacy 
needs more attention in the future 
 Further studies are also warranted to assess the cost-effectiveness of lesion vs. field targeted 
treatment, and the cost-effectiveness of the novel treatment protocol with BF-200 ALA in DL-PDT  
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